Provider: NIHR Journals Library
Content:text/plain; charset="UTF-8"
TY  - JOUR
LB  - 1.
AU  - Scott, DL
AU  - Steer, S
TI  - The course of established rheumatoid arthritis
J2  - Best Pract Res Clin Rheumatol
PY  - 2007
VL  - 21
SP  - 943
EP  - 967
UR  - https://doi.org/10.1016/j.berh.2007.05.006
ER  - 
TY  - JOUR
LB  - 2.
AU  - Pincus, T
AU  - Fuchs, HA
AU  - Callahan, LF
AU  - Nance, EP, Jr
AU  - Kaye, JJ
TI  - Early radiographic joint space narrowing and erosion and later malalignment in rheumatoid arthritis: a longitudinal analysis
J2  - J Rheumatol
PY  - 1998
VL  - 25
SP  - 636
EP  - 640
ER  - 
TY  - JOUR
LB  - 3.
AU  - Drossaers-Bakker, KW
AU  - Kroon, HM
AU  - Zwinderman, AH
AU  - Breedveld, FC
AU  - Hazes, JM
TI  - Radiographic damage of large joints in long-term rheumatoid arthritis and its relation to function
J2  - Rheumatology
PY  - 2000
VL  - 39
SP  - 998
EP  - 1003
UR  - https://doi.org/10.1093/rheumatology/39.9.998
ER  - 
TY  - BOOK
LB  - 4.
AU  - National Collaborating Centre for Chronic Conditions
TI  - Rheumatoid Arthritis: National Clinical Guideline for Management and Treatment in Adults
CY  - London
PB  - Royal College of Physicians
PY  - 2009
ER  - 
TY  - JOUR
LB  - 5.
AU  - Naz, SM
AU  - Symmons, DP
TI  - Mortality in established rheumatoid arthritis
J2  - Best Pract Res Clin Rheumatol
PY  - 2007
VL  - 21
SP  - 871
EP  - 883
UR  - https://doi.org/10.1016/j.berh.2007.05.003
ER  - 
TY  - JOUR
LB  - 6.
AU  - Dadoun, S
AU  - Zeboulon-Ktorza, N
AU  - Combescure, C
AU  - Elhai, M
AU  - Rozenberg, S
AU  - Gossec, L
TI  - Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis
J2  - Joint Bone Spine
PY  - 2013
VL  - 80
SP  - 29
EP  - 33
UR  - https://doi.org/10.1016/j.jbspin.2012.02.005
ER  - 
TY  - JOUR
LB  - 7.
AU  - Meune, C
AU  - Touze, E
AU  - Trinquart, L
AU  - Allanore, Y
TI  - Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies
J2  - Rheumatology
PY  - 2009
VL  - 48
SP  - 1309
EP  - 1313
UR  - https://doi.org/10.1093/rheumatology/kep252
ER  - 
TY  - JOUR
LB  - 8.
AU  - Pugner, KM
AU  - Scott, DI
AU  - Holmes, JW
AU  - Hieke, K
TI  - The costs of rheumatoid arthritis: an international long-term view
J2  - Semin Arthritis Rheum
PY  - 2000
VL  - 29
SP  - 305
EP  - 320
UR  - https://doi.org/10.1016/S0049-0172(00)80017-7
ER  - 
TY  - JOUR
LB  - 9.
AU  - Symmons, D
AU  - Tricker, K
AU  - Roberts, C
AU  - Davies, L
AU  - Dawes, P
AU  - Scott, DL
TI  - The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis
J2  - Health Technol Assess
PY  - 2005
VL  - 9
IS  - 34
UR  - https://doi.org/10.3310/hta9340
ER  - 
TY  - JOUR
LB  - 10.
AU  - Symmons, D
AU  - Turner, G
AU  - Webb, R
AU  - Asten, P
AU  - Barrett, E
AU  - Lunt, M
TI  - The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century
J2  - Rheumatology
PY  - 2002
VL  - 41
SP  - 793
EP  - 800
UR  - https://doi.org/10.1093/rheumatology/41.7.793
ER  - 
TY  - JOUR
LB  - 11.
AU  - Symmons, DP
AU  - Barrett, EM
AU  - Bankhead, CR
AU  - Scott, DG
AU  - Silman, AJ
TI  - The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register
J2  - Br J Rheumatol
PY  - 1994
VL  - 33
SP  - 735
EP  - 739
UR  - https://doi.org/10.1093/rheumatology/33.8.735
ER  - 
TY  - JOUR
LB  - 12.
AU  - Alamanos, Y
AU  - Drosos, AA
TI  - Epidemiology of adult rheumatoid arthritis
J2  - Autoimmun Rev
PY  - 2005
VL  - 4
SP  - 130
EP  - 136
UR  - https://doi.org/10.1016/j.autrev.2004.09.002
ER  - 
TY  - BOOK
LB  - 13.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab and Abatacept for Rheumatoid Arthritis Not Previously Treated With DMARDs or After Conventional DMARDs Only Have Failed
CY  - London
PB  - NICE
PY  - 2016
ER  - 
TY  - BOOK
LB  - 14.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a TNF Inhibitor
CY  - London
PB  - NICE
PY  - 2010
ER  - 
TY  - BOOK
LB  - 15.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Tocilizumab for the Treatment of Rheumatoid Arthritis (Rapid Review of Technology Appraisal Guidance 198)
CY  - London
PB  - NICE
PY  - 2012
ER  - 
TY  - BOOK
LB  - 16.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Anti-Rheumatic Drugs
CY  - London
PB  - NICE
PY  - 2011
ER  - 
TY  - JOUR
LB  - 17.
AU  - Smolen, JS
AU  - Breedveld, FC
AU  - Burmester, GR
AU  - Bykerk, V
AU  - Dougados, M
AU  - Emery, P
TI  - Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
J2  - Ann Rheum Dis
PY  - 2016
VL  - 75
SP  - 3
EP  - 15
UR  - https://doi.org/10.1136/annrheumdis-2015-207524
ER  - 
TY  - JOUR
LB  - 18.
AU  - Smolen, JS
AU  - Aletaha, D
AU  - Bijlsma, JW
AU  - Breedveld, FC
AU  - Boumpas, D
AU  - Burmester, G
TI  - Treating rheumatoid arthritis to target: recommendations of an international task force
J2  - Ann Rheum Dis
PY  - 2010
VL  - 69
SP  - 631
EP  - 637
UR  - https://doi.org/10.1136/ard.2009.123919
ER  - 
TY  - JOUR
LB  - 19.
AU  - Felson, DT
AU  - Smolen, JS
AU  - Wells, G
AU  - Zhang, B
AU  - Van Tuyl, LHD
AU  - Funovits, J
TI  - American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
J2  - Arthritis Rheum
PY  - 2011
VL  - 63
SP  - 573
EP  - 586
UR  - https://doi.org/10.1002/art.30129
ER  - 
TY  - JOUR
LB  - 20.
AU  - Solomon, DH
AU  - Bitton, A
AU  - Katz, JN
AU  - Radner, H
AU  - Brown, EM
AU  - Fraenkel, L
J2  - Review: Treat to Target in Rheumatoid Arthritis: Fact, Fiction, or Hypothesis?
PY  - 2014
VL  - 66
SP  - 775
EP  - 782
UR  - https://doi.org/10.1002/art.38323
ER  - 
TY  - JOUR
LB  - 21.
AU  - Jurgens, MS
AU  - Welsing, PM
AU  - Jacobs, JW
TI  - Overview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission
J2  - Clin Exp Rheumatol
PY  - 2012
VL  - 30
IS  - Suppl. 4
SP  - 56
EP  - 63
ER  - 
TY  - JOUR
LB  - 22.
AU  - Scott, DL
AU  - Ibrahim, F
AU  - Farewell, V
AU  - O’Keeffe, AG
AU  - Ma, M
AU  - Walker, D
TI  - Randomised controlled trial of Tumour necrosis factor inhibitors Against Combination Intensive Therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews
J2  - Health Technol Assess
PY  - 2014
VL  - 18
IS  - 66
UR  - https://doi.org/10.3310/hta18660
ER  - 
TY  - JOUR
LB  - 23.
AU  - Schoels, M
AU  - Knevel, R
AU  - Aletaha, D
AU  - Bijlsma, JW
AU  - Breedveld, FC
AU  - Boumpas, DT
TI  - Evidence for treating rheumatoid arthritis to target: results of a systematic literature search
J2  - Ann Rheum Dis
PY  - 2010
VL  - 69
SP  - 638
EP  - 643
UR  - https://doi.org/10.1136/ard.2009.123976
ER  - 
TY  - CHAP
LB  - 24.
AU  - Higgins, JPT
AU  - Altman, DG
AU  - Cochrane Statistical Methods Group
AU  - Cochrane Bias Methods Group
TI  - Chapter 8: Assessing Risk of Bias in Included studies
A2  - Higgins, JPT
A2  - Green, S
T2  - Cochrane Handbook for Systematic Reviews of Interventions Version 510 [updated March 2011]: The Cochrane Collaboration
UR  - www.handbook.cochrane.org
Y2  - 15 August 2016
ER  - 
TY  - JOUR
LB  - 25.
AU  - Wright, CC
AU  - Sim, J
TI  - Intention-to-treat approach to data from randomized controlled trials: a sensitivity analysis
J2  - J Clin Epidemiol
PY  - 2003
VL  - 56
SP  - 833
EP  - 842
UR  - https://doi.org/10.1016/S0895-4356(03)00155-0
ER  - 
TY  - JOUR
LB  - 26.
AU  - Allaart, CF
AU  - Breedveld, FC
AU  - Dijkmans, BA
TI  - Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study
J2  - J Rheumatol Suppl
PY  - 2007
VL  - 80
SP  - 25
EP  - 33
ER  - 
TY  - JOUR
LB  - 27.
AU  - Allaart, CF
AU  - Geokoop-Ruiterman, YPM
AU  - de Vries-Bouwstra, JK
AU  - Breedveld, FC
AU  - Dijkmans, BAC
TI  - Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: The BeSt study
J2  - Clin Exp Rheumatol
PY  - 2006
VL  - 24
SP  - S77
EP  - S82
ER  - 
TY  - JOUR
LB  - 28.
AU  - Dirven, L
AU  - Bek, M
AU  - Klarenbeek, NB
AU  - Han, KH
AU  - Ronday, HK
AU  - Kerstens, P
TI  - Eight year results of disease activity steered treatment in a large recent rheumatoid arthritis cohort: clinical and radiological outcomes
J2  - Arthritis Rheum
PY  - 2011
VL  - 63
IS  - Suppl. 10
SP  - 2200
ER  - 
TY  - JOUR
LB  - 29.
AU  - Dirven, L
AU  - van den Broek, M
AU  - Klarenbeek, NB
AU  - Van Krugten, MV
AU  - Van Der Lubbe, PAHM
AU  - Kerstens, PJSM
TI  - Seven year results of DAS steered treatment in the best study: clinical and radiological outcomes
J2  - Arthritis Rheum
PY  - 2010
VL  - 62
SP  - 334
ER  - 
TY  - JOUR
LB  - 30.
AU  - Goekoop-Ruiterman, YP
AU  - de Vries-Bouwstra, JK
AU  - Allaart, CF
AU  - van Zeben, D
AU  - Kerstens, PJ
AU  - Hazes, JM
TI  - Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial
J2  - Arthritis Rheum
PY  - 2005
VL  - 52
SP  - 3381
EP  - 3390
UR  - https://doi.org/10.1002/art.21405
ER  - 
TY  - JOUR
LB  - 31.
AU  - Klarenbeek, NB
AU  - Güler-Yüksel, M
AU  - van der Kooij, SM
AU  - Han, KH
AU  - Ronday, HK
AU  - Kerstens, PJ
TI  - The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study
J2  - Ann Rheum Dis
PY  - 2011
VL  - 70
SP  - 1039
EP  - 1046
UR  - https://doi.org/10.1136/ard.2010.141234
ER  - 
TY  - JOUR
LB  - 32.
AU  - Koevoets, R
AU  - Dirven, L
AU  - Klarenbeek, NB
AU  - van Krugten, MV
AU  - Ronday, HK
AU  - van der Heijde, DM
TI  - ‘Insights in the relationship of joint space narrowing versus erosive joint damage and physical functioning of patients with RA’
J2  - Ann Rheum Dis
PY  - 2013
VL  - 72
SP  - 870
EP  - 874
UR  - https://doi.org/10.1136/annrheumdis-2011-201191
ER  - 
TY  - JOUR
LB  - 33.
AU  - Markusse, IM
AU  - Dirven, L
AU  - Van Groenendael, JH
AU  - Han, KH
AU  - Ronday, HK
AU  - Kerstens, PJSM
TI  - Mortality in a large cohort of patients with early rheumatoid arthritis that were treated-to-target for 10 years
J2  - Arthritis Rheumatol
PY  - 2014
VL  - 66
SP  - S359
ER  - 
TY  - JOUR
LB  - 34.
AU  - van den Broek, M
AU  - Dirven, L
AU  - Klarenbeek, N
AU  - Krugten, M
AU  - Ronday, H
AU  - Kerstens, P
TI  - Clinical and radiological outcomes of four disease activity driven treatment strategies: 8-year results of the best study
J2  - Ann Rheum Dis
PY  - 2013
VL  - 71
SP  - 106
UR  - https://doi.org/10.1136/annrheumdis-2012-eular.1837
ER  - 
TY  - JOUR
LB  - 35.
AU  - Verstappen, SM
AU  - Bakker, MF
AU  - Heurkens, AH
AU  - van der Veen, MJ
AU  - Kruize, AA
AU  - Geurts, MA
TI  - Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study
J2  - Ann Rheum Dis
PY  - 2010
VL  - 69
SP  - 1044
EP  - 1048
UR  - https://doi.org/10.1136/ard.2008.106617
ER  - 
TY  - JOUR
LB  - 36.
AU  - Verstappen, SM
AU  - Jacobs, JW
AU  - Veen, MJ
AU  - Heurkens, AH
AU  - Schenk, Y
AU  - ter Borg, EJ
TI  - Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)
J2  - Ann Rheum Dis
PY  - 2007
VL  - 66
SP  - 1443
EP  - 1449
UR  - https://doi.org/10.1136/ard.2007.071092
ER  - 
TY  - JOUR
LB  - 37.
AU  - Bakker, MF
AU  - Jacobs, JWG
AU  - Welsing, PMJ
AU  - Verstappen, SMM
AU  - Tekstra, J
AU  - Ton, E
TI  - Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial
J2  - Ann Intern Med
PY  - 2012
VL  - 156
SP  - 329
EP  - 339
UR  - https://doi.org/10.7326/0003-4819-156-5-201203060-00004
ER  - 
TY  - JOUR
LB  - 38.
AU  - De Cock, D
AU  - Meyfroidt, S
AU  - Joly, J
AU  - Van der Elst, K
AU  - Westhovens, R
AU  - Verschueren, P
TI  - For remission induction with glucocorticoid bridging, methotrexate monotherapy is as effective as a combination with other DMARDs, with fewer reported side effects: 4 month primary outcome of care, a randomized induction strategy and treat to target trial in early rheumatoid arthritis
J2  - Arthritis Rheum
PY  - 2013
VL  - 65
SP  - 3325
EP  - 3326
ER  - 
TY  - JOUR
LB  - 39.
AU  - De Cock, D
AU  - Westhovens, R
AU  - Corluy, L
AU  - Joos, R
AU  - Langenaken, C
AU  - Taelman, V
TI  - Comparison of MTX therapy with or without a moderate dose glucocorticoid bridging scheme in early rheumatoid arthritis patients lacking classical poor prognostic markers: week 16 results from the randomized multicenter carera trial
J2  - Ann Rheum Dis
PY  - 2014
VL  - 73
SP  - 220
UR  - https://doi.org/10.1136/annrheumdis-2014-eular.2144
ER  - 
TY  - JOUR
LB  - 40.
AU  - Verschueren, P
AU  - Cock, D
AU  - Corluy, L
AU  - Joos, R
AU  - Langenaken, C
AU  - Taelman, V
TI  - Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial
J2  - Arthritis Res Ther
PY  - 2015
VL  - 17
SP  - 97
UR  - https://doi.org/10.1186/s13075-015-0611-8
ER  - 
TY  - JOUR
LB  - 41.
AU  - Verschueren, P
AU  - Cock, D
AU  - Corluy, L
AU  - Joos, R
AU  - Langenaken, C
AU  - Taelman, V
TI  - Associated with a glucocorticoid bridging scheme, methotrexate is as effective alone as in combination with other DMARDs for early rheumatoid arthritis, with fewer reported side effects: 16 weeks remission induction data from the carera trial
J2  - Ann Rheum Dis
PY  - 2014
VL  - 73
UR  - https://doi.org/10.1136/annrheumdis-2014-eular.2137
ER  - 
TY  - JOUR
LB  - 42.
AU  - Verschueren, P
AU  - Cock, D
AU  - Corluy, L
AU  - Joos, R
AU  - Langenaken, C
AU  - Taelman, V
TI  - Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial
J2  - Ann Rheum Dis
PY  - 2015
VL  - 74
SP  - 27
EP  - 34
UR  - https://doi.org/10.1136/annrheumdis-2014-205489
ER  - 
TY  - JOUR
LB  - 43.
AU  - Verschueren, P
AU  - De Cock, D
AU  - Corluy, L
AU  - Joos, R
AU  - Langenaken, C
AU  - Taelman, V
TI  - Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial
J2  - Ann Rheum Dis
PY  - 2017
VL  - 76
SP  - 511
EP  - 520
UR  - https://doi.org/10.1136/annrheumdis-2016-209212
ER  - 
TY  - JOUR
LB  - 44.
AU  - den Uyl, D
AU  - ter Wee, M
AU  - Boers, M
AU  - Kerstens, P
AU  - Voskuyl, A
AU  - Nurmohamed, M
TI  - A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks
J2  - Ann Rheum Dis
PY  - 2014
VL  - 73
SP  - 1071
EP  - 1078
UR  - https://doi.org/10.1136/annrheumdis-2012-202818
ER  - 
TY  - JOUR
LB  - 45.
AU  - ter Wee, MM
AU  - den Uyl, D
AU  - Boers, M
AU  - Kerstens, P
AU  - Nurmohamed, M
AU  - van Schaardenburg, D
TI  - Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional ETN: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial
J2  - Ann Rheum Dis
PY  - 2015
VL  - 74
SP  - 1233
EP  - 1240
UR  - https://doi.org/10.1136/annrheumdis-2013-205143
ER  - 
TY  - JOUR
LB  - 46.
AU  - Mottonen, T
AU  - Hannonen, P
AU  - Leirisalo-Repo, M
AU  - Nissila, M
AU  - Kautiainen, H
AU  - Korpela, M
TI  - Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial
J2  - Lancet
PY  - 1999
VL  - 353
SP  - 1568
EP  - 1573
UR  - https://doi.org/10.1016/S0140-6736(98)08513-4
ER  - 
TY  - JOUR
LB  - 47.
AU  - Rantalaiho, V
AU  - Korpela, M
AU  - Hannonen, P
AU  - Kautiainen, H
AU  - Järvenpää, S
AU  - Leirisalo-Repo, M
TI  - The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial
J2  - Arthritis Rheum
PY  - 2009
VL  - 60
SP  - 1222
EP  - 1231
UR  - https://doi.org/10.1002/art.24447
ER  - 
TY  - JOUR
LB  - 48.
AU  - Rantalaiho, V
AU  - Korpela, M
AU  - Laasonen, L
AU  - Kautiainen, H
AU  - Järvenpää, S
AU  - Hannonen, P
TI  - Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial
J2  - Arthritis Res Ther
PY  - 2010
VL  - 12
SP  - R122
UR  - https://doi.org/10.1186/ar3060
ER  - 
TY  - JOUR
LB  - 49.
AU  - Rantalaiho, V
AU  - Puolakka, K
AU  - Korpela, M
AU  - Hannonen, P
AU  - Mottonen, T
TI  - Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis
J2  - Clin Exp Rheumatol
PY  - 2012
VL  - 30
SP  - S27
EP  - S31
ER  - 
TY  - JOUR
LB  - 50.
AU  - Fransen, J
AU  - Moens, HB
AU  - Speyer, I
AU  - van Riel, PL
TI  - Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial
J2  - Ann Rheum Dis
PY  - 2005
VL  - 64
SP  - 1294
EP  - 1298
UR  - https://doi.org/10.1136/ard.2004.030924
ER  - 
TY  - JOUR
LB  - 51.
AU  - Hodkinson, B
AU  - Musenge, E
AU  - Tikly, M
TI  - Tight control of rheumatoid arthritis in a resource-constrained setting: A randomized controlled study comparing the clinical disease activity index and simplified disease activity index
J2  - Rheumatol
PY  - 2015
VL  - 54
SP  - 1033
EP  - 1038
UR  - https://doi.org/10.1093/rheumatology/keu443
ER  - 
TY  - JOUR
LB  - 52.
AU  - Pope, JE
AU  - Haraoui, B
AU  - Rampakakis, E
AU  - Psaradellis, E
AU  - Thorne, C
AU  - Sampalis, JS
TI  - Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial
J2  - Arthritis Care Res
PY  - 2013
VL  - 65
SP  - 1401
EP  - 1409
UR  - https://doi.org/10.1002/acr.22010
ER  - 
TY  - JOUR
LB  - 53.
AU  - Pope, JE
AU  - Thorne, JC
AU  - Haraoui, B
AU  - Sampalis, J
TI  - Treating to target with TNFi in active established rheumatoid arthritis results in longer drug survival than routine care with TNFi: results from the optimization of Humira RCT
J2  - Arthritis Rheum
PY  - 2010
VL  - 62
IS  - Suppl. 10
SP  - 344
ER  - 
TY  - JOUR
LB  - 54.
AU  - Saunders, SA
AU  - Capell, HA
AU  - Stirling, A
AU  - Vallance, R
AU  - Kincaid, W
AU  - McMahon, AD
TI  - Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies
J2  - Arthritis Rheum
PY  - 2008
VL  - 58
SP  - 1310
EP  - 1317
UR  - https://doi.org/10.1002/art.23449
ER  - 
TY  - JOUR
LB  - 55.
AU  - van Eijk, IC
AU  - Nielen, MM
AU  - van der Horst-Bruinsma, I
AU  - Tijhuis, GJ
AU  - Boers, M
AU  - Dijkmans, BA
TI  - Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial
J2  - Rheumatol
PY  - 2012
VL  - 51
SP  - 686
EP  - 689
UR  - https://doi.org/10.1093/rheumatology/ker355
ER  - 
TY  - JOUR
LB  - 56.
AU  - Urata, Y
AU  - Uesato, R
AU  - Tanaka, D
AU  - Nakamura, Y
AU  - Motomura, S
TI  - Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: treating to twin targets; t-4 study
J2  - Arthritis Rheum
PY  - 2011
VL  - 63
SP  - 534
EP  - 540
ER  - 
TY  - JOUR
LB  - 57.
AU  - Urata, Y
AU  - Uesato, R
AU  - Tanaka, D
AU  - Nakamura, Y
AU  - Motomura, S
TI  - Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 study
J2  - Ann Rheum Dis
PY  - 2012
VL  - 71
SP  - 534
EP  - 540
UR  - https://doi.org/10.1136/annrheumdis-2011-200108
ER  - 
TY  - JOUR
LB  - 58.
AU  - Moreland, LW
AU  - O’Dell, JR
AU  - Paulus, HE
AU  - Curtis, JR
AU  - Bathon, JM
AU  - St Clair, EW
TI  - A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis the treatment of early aggressive rheumatoid arthritis trial
J2  - Arthritis Rheum
PY  - 2012
VL  - 64
SP  - 2824
EP  - 2835
UR  - https://doi.org/10.1002/art.34498
ER  - 
TY  - JOUR
LB  - 59.
AU  - Moreland, LW
AU  - O’Dell, JR
AU  - Paulus, HE
AU  - Curtis, JR
AU  - Bathon, JM
AU  - St Clair, EW
TI  - Two-year radiographic results from the TEAR trial
J2  - Arthritis Rheum
PY  - 2010
VL  - 62
SP  - 1368
ER  - 
TY  - JOUR
LB  - 60.
AU  - O’Dell, JR
AU  - Curtis, JR
AU  - Mikuls, TR
AU  - Cofield, SS
AU  - Bridges, SL, Jr
AU  - Ranganath, VK
TI  - Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: Results from a two-year randomized, double-blind trial
J2  - Arthritis Rheum
PY  - 2013
VL  - 65
SP  - 1985
EP  - 1994
UR  - https://doi.org/10.1002/art.38012
ER  - 
TY  - JOUR
LB  - 61.
AU  - Grigor, C
AU  - Capell, H
AU  - Stirling, A
AU  - McMahon, AD
AU  - Lock, P
AU  - Vallance, R
TI  - Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
J2  - Lancet (North American Edition)
PY  - 2004
VL  - 364
SP  - 263
EP  - 269
UR  - https://doi.org/10.1016/S0140-6736(04)16676-2
ER  - 
TY  - JOUR
LB  - 62.
AU  - Bijlsma, JW
AU  - Welsing, PM
AU  - Woodworth, TG
AU  - Middelink, LM
AU  - Petho-Schramm, A
AU  - Bernasconi, C
TI  - Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial
J2  - Lancet
PY  - 2016
VL  - 388
SP  - 343
EP  - 355
UR  - https://doi.org/10.1016/S0140-6736(16)30363-4
ER  - 
TY  - JOUR
LB  - 63.
AU  - van Hulst, LT
AU  - Creemers, MC
AU  - Fransen, J
AU  - Li, LC
AU  - Grol, R
AU  - Hulscher, ME
TI  - How to improve DAS28 use in daily clinical practice? – a pilot study of a nurse-led intervention
J2  - Rheumatology
PY  - 2010
VL  - 49
SP  - 741
EP  - 748
UR  - https://doi.org/10.1093/rheumatology/kep407
ER  - 
TY  - JOUR
LB  - 64.
AU  - Markusse, IM
AU  - Akdemir, G
AU  - Dirven, L
AU  - Goekoop-Ruiterman, YP
AU  - van Groenendael, JH
AU  - Han, KH
TI  - Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial
J2  - Ann Int Med
PY  - 2016
VL  - 164
SP  - 523
EP  - 531
UR  - https://doi.org/10.7326/M15-0919
ER  - 
TY  - JOUR
LB  - 65.
AU  - van den Broek, M
AU  - Lems, WF
AU  - Allaart, CF
TI  - BeSt practice: the success of early-targeted treatment in rheumatoid arthritis
J2  - Clin Exp Rheumatol
PY  - 2012
VL  - 30
IS  - Suppl. 4
SP  - 35
EP  - 38
ER  - 
TY  - JOUR
LB  - 66.
AU  - van der Kooi, E
AU  - Klarenbeek, NB
AU  - Guler-Yuksel, M
AU  - Kerstens, P
AU  - van der Lubbe, P
AU  - Westedt, ML
TI  - A decrease in disease activity score (DAS) level is associated with a decrease in health assessment questionnaire (HAQ) score, independent of follow-up duration, during 5 years of tightly controlled treatment: results from the BeSt study
J2  - Ann Rheum Dis
PY  - 2011
VL  - 70
SP  - 168
EP  - 171
UR  - https://doi.org/10.1136/ard.2010.133132
ER  - 
TY  - JOUR
LB  - 67.
AU  - Bakker, MF
AU  - Jacobs, JW
AU  - Welsing, PM
AU  - Vreugdenhil, SA
AU  - van Booma-Frankfort, C
AU  - Linn-Rasker, SP
TI  - Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study
J2  - Ann Rheum Dis
PY  - 2011
VL  - 70
SP  - 1099
EP  - 1103
UR  - https://doi.org/10.1136/ard.2010.137943
ER  - 
TY  - JOUR
LB  - 68.
AU  - van der Kooij, SM
AU  - de Vries-Bouwstra, JK
AU  - Goekoop-Ruiterman, YP
AU  - Ewals, JA
AU  - Han, KH
AU  - Hazes, JM
TI  - Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis
J2  - Arthritis Rheum
PY  - 2009
VL  - 61
SP  - 4
EP  - 12
UR  - https://doi.org/10.1002/art.24367
ER  - 
TY  - JOUR
LB  - 69.
AU  - den Uyl, D
AU  - Ter Wee, MM
AU  - Boers, M
AU  - Voskuyl, AE
AU  - Kerstens, PJ
AU  - Nurmohamed, MT
TI  - Cobra-light therapy is clinically non-inferior to original cobra therapy in the treatment of early rheumatoid arthritis
J2  - Ann Rheum Dis
PY  - 2013
VL  - 71
SP  - 104
EP  - 105
UR  - https://doi.org/10.1136/annrheumdis-2012-eular.1834
ER  - 
TY  - JOUR
LB  - 70.
AU  - Rantalaiho, V
AU  - Kautiainen, H
AU  - Korpela, M
AU  - Mottonen, T
TI  - Targeted treatment and combination DMARD therapy are additively important for reaching remission in early rheumatoid arthritis
J2  - Ann Rheum Dis
PY  - 2013
VL  - 72
SP  - A588
UR  - https://doi.org/10.1136/annrheumdis-2013-eular.1752
ER  - 
TY  - JOUR
LB  - 71.
AU  - Pinals, RS
AU  - Masi, AT
AU  - Larsen, RA
TI  - Preliminary criteria for clinical remission in rheumatoid arthritis
J2  - Arthritis Rheum
PY  - 1981
VL  - 24
SP  - 130815
UR  - https://doi.org/10.002/art.1780241012
ER  - 
TY  - JOUR
LB  - 72.
AU  - Porter, DR
AU  - Grigor, C
AU  - Stirling, A
AU  - Capell, HA
TI  - A randomised controlled trial of a strategy of tight control of disease activity in rheumatoid arthritis – outcome over 18 months
J2  - Arthritis Rheum
PY  - 2003
VL  - 48
SP  - S232
ER  - 
TY  - JOUR
LB  - 73.
AU  - Felson, D
TI  - Defining remission in rheumatoid arthritis
J2  - Ann Rheum Dis
PY  - 2012
VL  - 71
IS  - Suppl. 2
SP  - i86
EP  - i88
UR  - https://doi.org/10.1136/annrheumdis-2011-200618
ER  - 
TY  - JOUR
LB  - 74.
AU  - Lillegraven, S
AU  - Prince, FH
AU  - Shadick, NA
AU  - Bykerk, VP
AU  - Lu, B
AU  - Frits, ML
TI  - Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort
J2  - Ann Rheum Dis
PY  - 2012
VL  - 71
SP  - 681
EP  - 686
UR  - https://doi.org/10.1136/ard.2011.154625
ER  - 
TY  - JOUR
LB  - 75.
AU  - Lisbona, MP
AU  - Solano, A
AU  - Ares, J
AU  - Almirall, M
AU  - Salman-Monte, TC
AU  - Maymó, J
TI  - ACR/EULAR definitions of remission are associated with lower residual inflammatory activity compared with DAS28 remission on hand MRI in rheumatoid arthritis
J2  - J Rheumatol
PY  - 2016
VL  - 43
SP  - 1631
EP  - 1636
UR  - https://doi.org/10.3899/jrheum.150849
ER  - 
TY  - JOUR
LB  - 76.
AU  - Thiele, K
AU  - Huscher, D
AU  - Bischoff, S
AU  - Späthling-Mestekemper, S
AU  - Backhaus, M
AU  - Aringer, M
TI  - Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis
J2  - Ann Rheum Dis
PY  - 2013
VL  - 72
SP  - 1194
EP  - 1199
UR  - https://doi.org/10.1136/annrheumdis-2012-201821
ER  - 
TY  - JOUR
LB  - 77.
AU  - Van Tuyl, LHD
AU  - Britsemmer, K
AU  - Wells, GA
AU  - Smolen, JS
AU  - Zhang, B
AU  - Funovits, J
TI  - Remission in early rheumatoid arthritis defined by 28 joint counts: limited consequences of residual disease activity in the forefeet on outcome
J2  - Ann Rheum Dis
PY  - 2012
VL  - 71
SP  - 33
EP  - 37
UR  - https://doi.org/10.1136/ard.2011.153742
ER  - 
TY  - JOUR
LB  - 78.
AU  - Zufferey, P
AU  - Möller, B
AU  - Brulhart, L
AU  - Tamborrini, G
AU  - Scherer, A
AU  - Finckh, A
TI  - Persistence of ultrasound synovitis in patients with rheumatoid arthritis fulfilling the DAS28 and/or the new ACR/EULAR RA remission definitions: results of an observational cohort study
J2  - Joint Bone Spine
PY  - 2014
VL  - 81
SP  - 426
EP  - 432
UR  - https://doi.org/10.1016/j.jbspin.2014.04.014
ER  - 
TY  - JOUR
LB  - 79.
AU  - Stoffer, MA
AU  - Schoels, MM
AU  - Smolen, JS
AU  - Aletaha, D
AU  - Breedveld, FC
AU  - Burmester, G
TI  - Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update
J2  - Ann Rheum Dis
PY  - 2016
VL  - 75
SP  - 16
EP  - 22
UR  - https://doi.org/10.1136/annrheumdis-2015-207526
ER  - 
TY  - JOUR
LB  - 80.
AU  - Schipper, LG
AU  - van Hulst, LT
AU  - Grol, R
AU  - van Riel, PL
AU  - Hulscher, ME
AU  - Fransen, J
TI  - Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome
J2  - Rheumatol
PY  - 2010
VL  - 49
SP  - 2154
EP  - 2164
UR  - https://doi.org/10.1093/rheumatology/keq195
ER  - 
TY  - JOUR
LB  - 81.
AU  - Bakker, MF
AU  - Jacobs, JW
AU  - Verstappen, SM
AU  - Bijlsma, JW
TI  - Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility
J2  - Ann Rheum Dis
PY  - 2007
VL  - 66
IS  - Suppl. 3
SP  - iii56
EP  - iii60
UR  - https://doi.org/10.1136/ard.2007.078360
ER  - 
TY  - JOUR
LB  - 82.
AU  - Knevel, R
AU  - Schoels, M
AU  - Huizinga, TWJ
AU  - Aletaha, D
AU  - Burmester, GR
AU  - Combe, B
TI  - Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
J2  - Ann Rheum Dis
PY  - 2010
VL  - 69
SP  - 987
EP  - 994
UR  - https://doi.org/10.1136/ard.2009.126748
ER  - 
TY  - JOUR
LB  - 83.
AU  - Husereau, D
AU  - Drummond, M
AU  - Petrou, S
AU  - Carswell, C
AU  - Moher, D
AU  - Greenberg, D
TI  - Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
J2  - BMJ
PY  - 2013
VL  - 346
SP  - f1049
UR  - https://doi.org/10.1136/bmj.f1049
ER  - 
TY  - JOUR
LB  - 84.
AU  - Husereau, D
AU  - Drummond, M
AU  - Petrou, S
AU  - Carswell, C
AU  - Moher, D
AU  - Greenberg, D
TI  - Consolidated Health Economic Evaluation Reporting Standards (CHEERS) – explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
J2  - Value Health
PY  - 2013
VL  - 16
SP  - 231
EP  - 250
UR  - https://doi.org/10.1016/j.jval.2013.02.002
ER  - 
TY  - JOUR
LB  - 85.
AU  - Vermeer, M
AU  - Kievit, W
AU  - Kuper, HH
AU  - Braakman-Jansen, LM
AU  - Bernelot Moens, HJ
AU  - Zijlstra, TR
TI  - Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry
J2  - BMC Musculoskelet Disord
PY  - 2013
VL  - 14
SP  - 350
UR  - https://doi.org/10.1186/1471-2474-14-350
ER  - 
TY  - JOUR
LB  - 86.
AU  - van den Hout, WB
AU  - Goekoop-Ruiterman, YP
AU  - Allaart, CF
AU  - de Vries-Bouwstra, JK
AU  - Hazes, JM
AU  - Kerstens, PJ
TI  - Cost–utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis
J2  - Arthritis Rheum
PY  - 2009
VL  - 61
SP  - 291
EP  - 299
UR  - https://doi.org/10.1002/art.24169
ER  - 
TY  - JOUR
LB  - 87.
AU  - Schett, G
AU  - Emery, P
AU  - Tanaka, Y
AU  - Burmester, G
AU  - Pisetsky, DS
AU  - Naredo, E
TI  - Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions
J2  - Ann Rheum Dis
PY  - 2016
VL  - 75
SP  - 1428
EP  - 1437
UR  - https://doi.org/10.1136/annrheumdis-2016-209201
ER  - 
TY  - JOUR
LB  - 88.
AU  - Barnabe, C
AU  - Nguyen Xuan, T
AU  - Ohinmaa, A
AU  - Homik, J
AU  - Barr, SG
AU  - Martin, L
TI  - Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission
J2  - Ann Rheum Dis
PY  - 2013
VL  - 72
SP  - 1664
EP  - 1668
UR  - https://doi.org/10.1136/annrheumdis-2012-201918
ER  - 
TY  - BOOK
LB  - 89.
AU  - Curtis, L
AU  - Burns, A
TI  - Unit Costs for Health & Social Care 2015
CY  - Canterbury
PB  - Personal Social Services Research Unit
PY  - 2015
ER  - 
TY  - BOOK
LB  - 90.
AU  - Curtis, L
TI  - Unit Costs for Health & Social Care 2010
CY  - Canterbury
PB  - Personal Social Services Research Unit
PY  - 2010
ER  - 
TY  - JOUR
LB  - 91.
AU  - Simpson, E
AU  - Hock, E
AU  - Stevenson, M
AU  - Wong, R
AU  - Dracup, N
AU  - Wailoo, A
TI  - What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis
J2  - Health Technol Assess
PY  - 2017
ER  - 
TY  - BOOK
LB  - 92.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Guide to the Methods of Technology Appraisal 2013
CY  - London
PB  - NICE
PY  - 2013
ER  - 
TY  - JOUR
LB  - 93.
AU  - Stevenson, M
AU  - Archer, R
AU  - Tosh, J
AU  - Simpson, E
AU  - Everson-Hock, E
AU  - Stevens, J
TI  - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
J2  - Health Technol Assess
PY  - 2016
VL  - 20
SP  - 1
EP  - 672
ER  - 
TY  - JOUR
LB  - 94.
AU  - Gaujoux-Viala, C
AU  - Mouterde, G
AU  - Baillet, A
AU  - Claudepierre, P
AU  - Fautrel, B
AU  - Le Loet, X
TI  - Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI
J2  - Joint Bone Spine
PY  - 2012
VL  - 79
SP  - 149
EP  - 155
UR  - https://doi.org/10.1016/j.jbspin.2011.04.008
ER  - 
TY  - JOUR
LB  - 95.
AU  - Salaffi, F
AU  - Cimmino, MA
AU  - Leardini, G
AU  - Gasparini, S
AU  - Grassi, W
TI  - Disease activity assessment of rheumatoid arthritis in daily practice: validity, internal consistency, reliability and congruency of the Disease Activity Score including 28 joints (DAS28) compared with the Clinical Disease Activity Index (CDAI)
J2  - Clin Exp Rheumatol
PY  - 2009
VL  - 27
SP  - 552
EP  - 559
ER  - 
TY  - JOUR
LB  - 96.
AU  - Singh, H
AU  - Kumar, H
AU  - Handa, R
AU  - Talapatra, P
AU  - Ray, S
AU  - Gupta, V
TI  - Use of clinical disease activity index score for assessment of disease activity in rheumatoid arthritis patients: an Indian experience
J2  - Arthritis
PY  - 2011
VL  - 2011
SP  - 146398
UR  - https://doi.org/10.1155/2011/146398
ER  - 
TY  - JOUR
LB  - 97.
AU  - Mian, A
AU  - Ibrahim, F
AU  - Scott, I
AU  - Bahadur, S
AU  - Filkova, M
AU  - Pollard, L
TI  - Changing clinical patterns in rheumatoid arthritis management over two decades: sequential observational studies
J2  - BMC Musculoskelet Disord
PY  - 2016
VL  - 17
UR  - https://doi.org/10.1186/s12891-016-0897-y
ER  - 
TY  - JOUR
LB  - 98.
AU  - Dougados, M
AU  - Kissel, K
AU  - Conaghan, PG
AU  - Mola, EM
AU  - Schett, G
AU  - Gerli, R
TI  - Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
J2  - Ann Rheum Dis
PY  - 2014
VL  - 73
SP  - 803
EP  - 809
UR  - https://doi.org/10.1136/annrheumdis-2013-204761
ER  - 
TY  - JOUR
LB  - 99.
AU  - Huizinga, TW
AU  - Conaghan, PG
AU  - Martin-Mola, E
AU  - Schett, G
AU  - Amital, H
AU  - Xavier, RM
TI  - Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study
J2  - Ann Rheum Dis
PY  - 2015
VL  - 74
SP  - 35
EP  - 43
UR  - https://doi.org/10.1136/annrheumdis-2014-205752
ER  - 
TY  - JOUR
LB  - 100.
AU  - Alemao, EA
AU  - Joo, S
AU  - Banerjee, S
AU  - Emery, P
AU  - Weinblatt, M
TI  - Impact of rapid attainment of stringent measures of efficacy in rheumatoid arthritis on patient-reported outcomes
J2  - Arthritis Rheumato
PY  - 2014
VL  - 66
SP  - S599
ER  - 
TY  - JOUR
LB  - 101.
AU  - Haavardsholm, EA
AU  - Aga, AB
AU  - Olsen, IC
AU  - Hammer, HB
AU  - Uhlig, T
AU  - Fremstad, H
TI  - Aiming for remission in rheumatoid arthritis: Clinical and radiographic outcomes from a randomized controlled strategy trial investigating the added value of ultrasonography in a treat-to-target regimen
J2  - Arthritis Rheumatol
PY  - 2015
VL  - 67
ER  - 
TY  - JOUR
LB  - 102.
AU  - Bijlsma, JW
AU  - Welsing, PM
AU  - Woodworth, TG
AU  - Middelink, LM
AU  - Bernasconi, C
AU  - Borm, ME
TI  - Rapid and sustained remission in early rheumatoid arthritis (RA) treated to target with tocilizumab, methotrexate, or their combination: The U-ACT-early strategy study
J2  - Ann Rheum Dis
PY  - 2015
VL  - 74
SP  - 77
EP  - 78
UR  - https://doi.org/10.1136/annrheumdis-2015-eular.2287
ER  - 
TY  - JOUR
LB  - 103.
AU  - Bakker, MF
AU  - Jacobs, JWG
AU  - Welsing, PMJ
AU  - Verstappen, SMM
AU  - Tekstra, J
AU  - Ton, E
TI  - Double-blind randomized CAMERA-II trial: better control of disease and erosive joint damage with inclusion of low-dose prednisone into a MTX-based tight control strategy for early rheumatoid arthritis
J2  - Arthritis Rheum
PY  - 2011
VL  - 1
ER  - 
TY  - JOUR
LB  - 104.
AU  - Bakker, MF
AU  - Jacobs, JWG
AU  - Welsing, PMJ
AU  - Verstappen, SMM
AU  - Tekstra, J
AU  - Ton, E
TI  - Double-blind randomized CAMERA-II trial: better control of disease and erosive joint damage with inclusion of low-dose prednisone into a MTX-based tight control strategy for early rheumatoid arthritis
J2  - Arthritis Rheum
PY  - 2011
VL  - 63
SP  - S663
EP  - S6S4
ER  - 
TY  - JOUR
LB  - 105.
AU  - De Hair, M
AU  - Ijff, N
AU  - Jacobs, J
AU  - Van Laar, J
TI  - Long-term adverse events after daily concomitant treatment with 10mg prednisone in the 2-year computer assisted management in early rheumatoid arthritis trial-ii
J2  - Arthritis Rheumat
PY  - 2015
VL  - 67
ER  - 
TY  - JOUR
LB  - 106.
AU  - Jurgens, M
AU  - Welsing, PM
AU  - Geenen, MJ
AU  - Bakker, MF
AU  - Lafeber, FP
AU  - Bijlsma, JW
TI  - Effect of prednisone on quality of life domains in early rheumatoid arthritis-additional analyses of the CAMERA II trial
J2  - Ann Rheum Dis
PY  - 2013
VL  - 71
UR  - https://doi.org/10.1136/annrheumdis-2012-eular.315
ER  - 
TY  - JOUR
LB  - 107.
AU  - Carubbi, F
AU  - Zugaro, L
AU  - Cipriani, P
AU  - Conchiglia, A
AU  - Gregori, L
AU  - Danniballe, C
TI  - Safety and efficacy of intra-articular anti-tumor necrosis factor alpha agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare
J2  - Int J Immunopathol Pharmacol
PY  - 2016
VL  - 29
SP  - 252
EP  - 266
UR  - https://doi.org/10.1177/0394632015593220
ER  - 
TY  - JOUR
LB  - 108.
AU  - Charles-Schoeman, C
AU  - Wang, X
AU  - Lee, YY
AU  - Shahbazian, A
AU  - Navarro-Millan, I
AU  - Yang, S
TI  - Association of triple therapy with improvement in cholesterol profiles over two-year follow-up in the treatment of early aggressive rheumatoid arthritis trial
J2  - Arthritis Rheum
PY  - 2016
VL  - 68
SP  - 577
EP  - 586
UR  - https://doi.org/10.1002/art.39502
ER  - 
TY  - JOUR
LB  - 109.
AU  - Hetland, ML
AU  - Horslev-Petersen, K
TI  - The CIMESTRA study: intra-articular glucocorticosteroids and synthetic DMARDs in a treat-to-target strategy in early rheumatoid arthritis
J2  - Clin Exp Rheumatol
PY  - 2012
VL  - 30
SP  - S44
EP  - S49
ER  - 
TY  - JOUR
LB  - 110.
AU  - Hetland, ML
AU  - Ostergaard, M
AU  - Ejbjerg, B
TI  - Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CR
J2  - Ann Rheum Dis
PY  - 2012
VL  - 71
SP  - 1918
UR  - https://doi.org/10.1136/annrheumdis-2011-200632
ER  - 
TY  - JOUR
LB  - 111.
AU  - Hetland, ML
AU  - Stengaard-Pedersen, K
AU  - Junker, P
AU  - Lottenburger, T
AU  - Hansen, I
AU  - Andersen, LS
TI  - Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study
J2  - Ann Rheum Dis
PY  - 2008
VL  - 67
SP  - 815
EP  - 822
UR  - https://doi.org/10.1136/ard.2007.076307
ER  - 
TY  - JOUR
LB  - 112.
AU  - Boers, M
AU  - Verhoeven, AC
AU  - Markusse, HM
AU  - Laar, MA
AU  - Westhovens, R
AU  - Denderen, JC
TI  - Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
J2  - Lancet
PY  - 1997
VL  - 350
SP  - 309
EP  - 318
UR  - https://doi.org/10.1016/S0140-6736(97)01300-7
ER  - 
TY  - JOUR
LB  - 113.
AU  - Korthals-de Bos, I
AU  - Tulder, M
AU  - Boers, M
AU  - Verhoeven, AC
AU  - Adèr, HJ
AU  - Bibo, J
TI  - Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone
J2  - J Rheumatol
PY  - 2004
VL  - 31
SP  - 1709
EP  - 1716
ER  - 
TY  - JOUR
LB  - 114.
AU  - Landewé, RB
AU  - Boers, M
AU  - Verhoeven, AC
AU  - Westhovens, R
AU  - van de Laar, MA
AU  - Markusse, HM
TI  - COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention
J2  - Arthritis Rheum
PY  - 2002
VL  - 46
SP  - 347
EP  - 356
UR  - https://doi.org/10.1002/art.10083
ER  - 
TY  - JOUR
LB  - 115.
AU  - van Tuyl, LH
AU  - Boers, M
AU  - Lems, WF
AU  - Landewé, RB
AU  - Han, H
AU  - van der Linden, S
TI  - Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis
J2  - Ann Rheum Dis
PY  - 2010
VL  - 69
SP  - 807
EP  - 812
UR  - https://doi.org/10.1136/ard.2009.108027
ER  - 
TY  - JOUR
LB  - 116.
AU  - Verhoeven, AC
AU  - Bibo, JC
AU  - Boers, M
AU  - Engel, GL
AU  - Van Der Linden, S
TI  - Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone
J2  - B J Rheumatol
PY  - 1998
VL  - 37
SP  - 1102
EP  - 1109
UR  - https://doi.org/10.1093/rheumatology/37.10.1102
ER  - 
TY  - JOUR
LB  - 117.
AU  - Dale, J
AU  - Stirling, A
AU  - Grigor, C
AU  - Saunders, S
AU  - Porter, D
TI  - Comparison of outcomes between studies of intensive treatment strategies in early RA from a single centre over 20 years
J2  - Ann Rheum Dis
PY  - 2015
VL  - 74
SP  - 670
UR  - https://doi.org/10.1136/annrheumdis-2015-eular.1980
ER  - 
TY  - JOUR
LB  - 118.
AU  - De Cock, D
AU  - Meyfroidt, S
AU  - Vanderschueren, G
AU  - Lateur, L
AU  - Joly, J
AU  - Westhovens, R
TI  - Two year radiological follow-up of early rheumatoid arthritis patients treated with initial step up monotherapy or initial step down therapy with glucocorticoids, followed by a tight control approach
J2  - Ann Rheum Dis
PY  - 2013
VL  - 72
SP  - 211
EP  - 212
UR  - https://doi.org/10.1136/annrheumdis-2013-eular.672
ER  - 
TY  - JOUR
LB  - 119.
AU  - De Cock, D
AU  - Vanderschueren, G
AU  - Meyfroidt, S
AU  - Joly, J
AU  - Westhovens, R
AU  - Verschueren, P
TI  - Two-year clinical and radiologic follow-up of early RA patients treated with initial step up monotherapy or initial step down therapy with glucocorticoids, followed by a tight control approach: lessons from a cohort study in daily practice
J2  - Clin Rheumatol
PY  - 2014
VL  - 33
SP  - 125
EP  - 130
UR  - https://doi.org/10.1007/s10067-013-2398-9
ER  - 
TY  - JOUR
LB  - 120.
AU  - De Cock, D
AU  - Corluy, L
AU  - Joos, R
AU  - Langenaken, C
AU  - Taelman, V
AU  - Raeman, F
TI  - Low-risk patients also benefit from remission induction treatment in early rheumatoid arthritis: Week 52 results from the carera trial
J2  - Ann Rheum Dis
PY  - 2015
VL  - 74
SP  - 236
EP  - 237
UR  - https://doi.org/10.1136/annrheumdis-2015-eular.3984
ER  - 
TY  - JOUR
LB  - 121.
AU  - den Broeder, AA
AU  - van Herwaarden, N
AU  - van der Maas, A
AU  - van den Hoogen, FH
AU  - Bijlsma, JW
AU  - van Vollenhoven, RF
TI  - Dose reduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study
J2  - BMC Musculoskelet Dis
PY  - 2013
VL  - 14
SP  - 299
UR  - https://doi.org/10.1186/1471-2474-14-299
ER  - 
TY  - JOUR
LB  - 122.
AU  - Dumitru, RB
AU  - Horton, S
AU  - Hodgson, R
AU  - Wakefield, RJ
AU  - Hensor, EM
AU  - Emery, P
TI  - A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed etanercept in patients with rheumatoid arthritis (VEDERA)
J2  - BMC Musculoskelet Dis
PY  - 2016
VL  - 17
SP  - 61
UR  - https://doi.org/10.1186/s12891-016-0915-0
ER  - 
TY  - JOUR
LB  - 123.
AU  - Emery, P
AU  - Mease, PJ
AU  - Rubbert-Roth, A
AU  - Curtis, JR
AU  - Muller-Ladner, U
AU  - Gaylis, NB
TI  - Retreatment with rituximab (RTX) based on a treatment to target (TT) approach provides better disease control than treatment as needed (PRN) in patients (PTS) with rheumatoid arthritis (RA)
J2  - Arthritis Rheum
PY  - 2009
VL  - 60
SP  - 2013
ER  - 
TY  - JOUR
LB  - 124.
AU  - Emery, P
AU  - Mease, PJ
AU  - Rubbert-Roth, A
AU  - Curtis, JR
AU  - Muller-Ladner, U
AU  - Gaylis, N
TI  - Comparison of two retreatment strategies with rituximab in patients with rheumatoid arthritis (RA)
J2  - Rheumatol
PY  - 2010
VL  - 49
SP  - i90
ER  - 
TY  - JOUR
LB  - 125.
AU  - Emery, P
AU  - Olszynski, W
AU  - Mease, P
TI  - Retreatment with rituximab (RTX) based on a treatment to target (TT) approach provides better disease control than treatment as needed (PRN) in patients with rheumatoid arthritis (RA)
J2  - J Rheumatol
PY  - 2010
VL  - 37
SP  - 1302
EP  - 1303
ER  - 
TY  - JOUR
LB  - 126.
AU  - Emery, P
AU  - Mease, PJ
AU  - Rubbert-Roth, A
AU  - Curtis, JR
AU  - Muller-Ladner, U
AU  - Gaylis, NB
TI  - Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis
J2  - Rheumatol
PY  - 2011
VL  - 50
SP  - 2223
EP  - 2232
UR  - https://doi.org/10.1093/rheumatology/ker253
ER  - 
TY  - JOUR
LB  - 127.
AU  - Fedorenko, E
AU  - Lukina, G
AU  - Sigidin, Y
TI  - Remission as the main therapeutic target: comparative efficacy of four treatment regimens in early rheumatoid arthritis (RA) patients (PTS)
J2  - Ann Rheum Dis
PY  - 2013
VL  - 72
SP  - A70
UR  - https://doi.org/10.1136/annrheumdis-2013-203223.15
ER  - 
TY  - JOUR
LB  - 128.
AU  - Ferraccioli, GF
AU  - Gremese, E
AU  - Tomietto, P
AU  - Favret, G
AU  - Damato, R
AU  - Di Poi, E
TI  - Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years
J2  - Rheumatology
PY  - 2002
VL  - 41
SP  - 892
EP  - 898
UR  - https://doi.org/10.1093/rheumatology/41.8.892
ER  - 
TY  - JOUR
LB  - 129.
AU  - Fiehn, C
AU  - Jacki, S
AU  - Heilig, B
AU  - Lampe, M
AU  - Wiesmüller, G
AU  - Richter, C
TI  - Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone
J2  - Rheumatol Int
PY  - 2007
VL  - 27
SP  - 975
EP  - 979
UR  - https://doi.org/10.1007/s00296-007-0347-0
ER  - 
TY  - JOUR
LB  - 130.
AU  - Galloway, JB
AU  - Kingsley, G
AU  - Ma, M
AU  - Lorente-Canovas, B
AU  - Cope, A
AU  - Ibrahim, F
TI  - Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial
J2  - Ann Rheum Dis
PY  - 2015
VL  - 74
SP  - 706
UR  - https://doi.org/10.1136/annrheumdis-2015-eular.4684
ER  - 
TY  - JOUR
LB  - 131.
AU  - Giacomelli, R
AU  - Cipriani, P
AU  - Cerinic, MM
AU  - Fulminis, A
AU  - Barattelli, G
AU  - Pingiotti, E
TI  - Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNF alpha production without decreasing TNF alpha mRNA levels. An in vivo and in vitro study
J2  - Clin Exp Rheumatol
PY  - 2002
VL  - 20
SP  - 365
EP  - 372
ER  - 
TY  - JOUR
LB  - 132.
AU  - Harrold, LR
AU  - Reed, GW
AU  - Harrington, JT
AU  - Barr, CJ
AU  - Saunders, KC
AU  - Gibofsky, A
TI  - A cluster-randomized trial of a behavioral intervention to incorporate a treat-to-target approach in the clinical care of rheumatoid arthritis patients
J2  - Ann Rheum Dis
PY  - 2015
VL  - 74
SP  - 988
EP  - 989
UR  - https://doi.org/10.1136/annrheumdis-2015-eular.2424
ER  - 
TY  - JOUR
LB  - 133.
AU  - Hørslev-Petersen, K
AU  - Hetland, ML
AU  - Junker, P
AU  - Podenphant, J
AU  - Ellingsen, T
AU  - Ahlqvist, P
TI  - Adalimumab added to methotrexate and intra-articular glucocorticoid increases remission rates at one year in early, DMARD-nave patients with rheumatoid arthritis an investigator-initiated randomized, controlled, double-blinded study
J2  - Arthritis Rheum
PY  - 2011
VL  - 63
IS  - Suppl. 10
SP  - 394
ER  - 
TY  - JOUR
LB  - 134.
AU  - Hwang, YG
AU  - Balasubramani, GK
AU  - Metes, ID
AU  - Levesque, MC
AU  - Bridges, SL
AU  - Moreland, LW
TI  - Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker
J2  - Arthritis Res Ther
PY  - 2016
VL  - 18
SP  - 108
UR  - https://doi.org/10.1186/s13075-016-1009-y
ER  - 
TY  - JOUR
LB  - 135.
AU  - Nam, JL
AU  - Villeneuve, E
AU  - Hensor, EM
AU  - Conaghan, PG
AU  - Keen, HI
AU  - Buch, MH
TI  - Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)
J2  - Ann Rheum Dis
PY  - 2014
VL  - 73
SP  - 75
EP  - 85
UR  - https://doi.org/10.1136/annrheumdis-2013-203440
ER  - 
TY  - JOUR
LB  - 136.
AU  - Nam, JL
AU  - Villeneuve, E
AU  - Hensor, EMA
AU  - Conaghan, PG
AU  - Keen, HI
AU  - Gough, AK
TI  - Inhibition of structural damage with two intensive treatment strategies using infliximab or high dose intravenous steroid followed by treat to target in DMARD naive rheumatoid arthritis (the IDEA study) – a preliminary report
J2  - Ann Rheum Dis
PY  - 2012
VL  - 71
SP  - 106
EP  - 107
ER  - 
TY  - JOUR
LB  - 137.
AU  - Moller-Bisgaard, S
AU  - Horslev-Petersen, K
AU  - Ejbjerg, BJ
AU  - Boesen, M
AU  - Hetland, ML
AU  - Christensen, R
TI  - Impact of a magnetic resonance imaging-guided treat-to-target strategy on disease activity and progression in patients with rheumatoid arthritis (the IMAGINE-RA trial): study protocol for a randomized controlled trial
J2  - Trials
PY  - 2015
VL  - 16
SP  - 178
UR  - https://doi.org/10.1186/s13063-015-0693-2
ER  - 
TY  - JOUR
LB  - 138.
AU  - Jalal, H
AU  - O’Dell, JR
AU  - Bridges, SL, Jr
AU  - Cofield, S
AU  - Curtis, JR
AU  - Mikuls, TR
TI  - Cost-effectiveness of triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis
J2  - Arthritis Care Res
PY  - 2016
VL  - 68
SP  - 1751
EP  - 1757
UR  - https://doi.org/10.1002/acr.22895
ER  - 
TY  - JOUR
LB  - 139.
AU  - Kume, K
AU  - Amano, K
AU  - Hatta, K
AU  - Ohta, H
TI  - Treating to target ultrasound with clinical remission better effects than clinical remission in RRP
J2  - Ann Rheum Dis
PY  - 2013
VL  - 71
SP  - 191
UR  - https://doi.org/10.1136/annrheumdis-2012-eular.2074
ER  - 
TY  - JOUR
LB  - 140.
AU  - Kuusalo, L
AU  - Puolakka, K
AU  - Kautiainen, H
AU  - Blåfield, H
AU  - Eklund, KK
AU  - Ilva, K
TI  - Impact of physicians’ adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial
J2  - Scand J Rheumatol
PY  - 2015
VL  - 44
SP  - 449
EP  - 455
UR  - https://doi.org/10.3109/03009742.2015.1043142
ER  - 
TY  - JOUR
LB  - 141.
AU  - Li, R
AU  - Zhao, JX
AU  - Su, Y
AU  - He, J
AU  - Chen, LN
AU  - Gu, F
TI  - High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial
J2  - Medicine
PY  - 2016
VL  - 95
SP  - e3968
UR  - https://doi.org/10.1097/MD.0000000000003968
ER  - 
TY  - JOUR
LB  - 142.
AU  - Marchesoni, A
AU  - Battafarano, N
AU  - Arreghini, M
AU  - Pellerito, R
AU  - Cagnoli, M
AU  - Prudente, P
TI  - Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis
J2  - Arthritis Rheum
PY  - 2002
VL  - 47
SP  - 59
EP  - 66
UR  - https://doi.org/10.1002/art1.10245
ER  - 
TY  - JOUR
LB  - 143.
AU  - Markusse, I
AU  - Dirven, L
AU  - Han, H
AU  - Ronday, K
AU  - Speyer, I
AU  - Kerstens, P
TI  - Survival in early rheumatoid arthritis patients after 10 years of targeted treatment
J2  - Ann Rheum Dis
PY  - 2015
VL  - 74
SP  - 84
EP  - 85
UR  - https://doi.org/10.1136/annrheumdis-2015-eular.1638
ER  - 
TY  - JOUR
LB  - 144.
AU  - Markusse, IM
AU  - Dirven, L
AU  - Han, KH
AU  - Ronday, HK
AU  - de Sonnaville, PB
AU  - Kerstens, PJ
TI  - Evaluating adherence to a treat-to-target protocol in recent-onset rheumatoid arthritis: reasons for compliance and hesitation
J2  - Arthritis Care Res
PY  - 2016
VL  - 68
SP  - 446
EP  - 453
UR  - https://doi.org/10.1002/acr.22681
ER  - 
TY  - JOUR
LB  - 145.
AU  - Capell, HA
AU  - Madhok, R
AU  - Porter, DR
AU  - Munro, RA
AU  - McInnes, IB
AU  - Hunter, JA
TI  - Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study
J2  - Ann Rheum Dis
PY  - 2007
VL  - 66
SP  - 235
EP  - 241
UR  - https://doi.org/10.1136/ard.2006.057133
ER  - 
TY  - JOUR
LB  - 146.
AU  - Hampson, R
AU  - Madhok, R
AU  - McInnes, I
AU  - Munro, R
AU  - Porter, D
AU  - Tierney, A
TI  - Methotrexate and sulphasalazine combination therapy (MASCOT) is more effective than either drug alone in patients with a sub-optimal response to sulphasazine monotherapy a double blind placebo randomised controlled trial (RCT)
J2  - Ann Rheum Dis
PY  - 2005
VL  - 64
SP  - 456
ER  - 
TY  - JOUR
LB  - 147.
AU  - Menon, N
AU  - Kothari, SY
AU  - Gogna, A
AU  - Sharma, R
TI  - Comparison of intra-articular glucocorticoid injections with DMARDs versus DMARDs alone in rheumatoid arthritis
J2  - J Assoc Physicians India
PY  - 2014
VL  - 62
SP  - 673
EP  - 676
ER  - 
TY  - JOUR
LB  - 148.
AU  - Moller-Bisgaard, S
AU  - Ejbjerg, BJ
AU  - Eshed, I
AU  - Horslev-Petersen, K
AU  - Jurik, AG
AU  - Vallo, J
TI  - Effect of methotrexate and intra-articular betamethasone with or without additional cyclosporine on magnetic resonance imaging (MRI)-determined inflammatory and destructive changes in very early rheumatoid arthritis-results from a 24-months’ randomised double blind placebo controlled trial
J2  - Ann Rheum Dis
PY  - 2015
VL  - 74
SP  - 648
UR  - https://doi.org/10.1136/annrheumdis-2015-eular.2808
ER  - 
TY  - JOUR
LB  - 149.
AU  - Montecucco, C
AU  - Todoerti, M
AU  - Sakellariou, G
AU  - Scire, CA
AU  - Caporali, R
TI  - Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study
J2  - Arthritis Res Ther
PY  - 2012
VL  - 14
SP  - R112
UR  - https://doi.org/10.1186/ar3838
ER  - 
TY  - JOUR
LB  - 150.
AU  - Kuusalo, L
AU  - Rantalaiho, V
AU  - Kautiainen, H
AU  - Korpela, M
AU  - Puolakka, K
AU  - Leirisalo-Repo, M
TI  - Impact of physicians’ activity and adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis: a subanalysis of the Neo-RACo trial
J2  - Scand J Rheumatol
PY  - 2014
VL  - 43
SP  - 1
EP  - 2
ER  - 
TY  - JOUR
LB  - 151.
AU  - Leirisalo-Repo, M
AU  - Kautiainen, H
AU  - Laasonen, L
AU  - Mottonen, T
AU  - Hannonen, P
AU  - Korpela, M
TI  - A randomized double-blind placebo-controlled study on addition of 6-month induction therapy with infliximab to triple DMARD plus prednisolone therapy in patients with early active rheumatoid arthritis: High remission rates and no joint destruction during first 2 years. The NEO-RACo study
J2  - Rheumatol
PY  - 2009
VL  - 48
SP  - i11
EP  - ii2
ER  - 
TY  - JOUR
LB  - 152.
AU  - Rantalaiho, V
AU  - Kautiainen, H
AU  - Korpela, M
AU  - Hannonen, P
AU  - Kaipiainen-Seppänen, O
AU  - Möttönen, T
TI  - Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial
J2  - Ann Rheum Dis
PY  - 2014
VL  - 73
SP  - 1954
EP  - 1961
UR  - https://doi.org/10.1136/annrheumdis-2013-203497
ER  - 
TY  - JOUR
LB  - 153.
AU  - Rantalaiho, V
AU  - Kautiainen, H
AU  - Korpela, M
AU  - Leirisalo-Repo, M
TI  - Strict ACR-remission within 6 months predicts sustained long-term very low disease activity in actively treated rheumatoid arthritis patients, 5-year results of the NEO-RACo trial
J2  - Ann Rheum Dis
PY  - 2013
VL  - 72
UR  - https://doi.org/10.1136/annrheumdis-2013-eular.1754
ER  - 
TY  - JOUR
LB  - 154.
AU  - Rantalaiho, V
AU  - Korpela, M
AU  - Hannonen, P
AU  - Kaipiainen-Seppanen, O
AU  - Mottonen, T
AU  - Kauppi, M
TI  - Targeted treatment with combination dMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. the 5-year follow-up results of the NEO-RACo trial
J2  - Ann Rheum Dis
PY  - 2012
VL  - 71
SP  - 103
ER  - 
TY  - JOUR
LB  - 155.
AU  - Rantalaiho, V
AU  - Martikainen, J
AU  - Kautiainen, H
AU  - Puolakka, K
AU  - Leirisalo-Repo, M
TI  - Initial infliximab is not cost-effective added on to a remission-targeted combination therapy in early rheumatoid arthritis: the 2-year results of the randomized clinical NEO-RACo trial
J2  - Scand J Rheumatol
PY  - 2014
VL  - 43
SP  - 1
ER  - 
TY  - JOUR
LB  - 156.
AU  - Rantalaiho, V
AU  - Martikainen, J
AU  - Kautiainen, H
AU  - Puolakka, K
AU  - Leirisalo-Repo, M
TI  - Initial infliximab is not cost-effective in otherwise actively treated early rheumatoid arthritis. The 2-year follow-up results of the randomized clinical NEO-RACo trial
J2  - Ann Rheum Dis
PY  - 2014
VL  - 73
UR  - https://doi.org/10.1136/annrheumdis-2014-eular.3265
ER  - 
TY  - JOUR
LB  - 157.
AU  - Rantalaiho, V
AU  - Puolakka, K
AU  - Martikainen, J
AU  - Kautiainen, H
AU  - Leirisalo-Repo, M
TI  - Adding an initial six-month course of infliximab to an active combination treatment is cost saving in working-aged early rheumatoid arthritis patients
J2  - Arthritis Rheumatol
PY  - 2014
VL  - 66
SP  - S1083
EP  - S10S4
ER  - 
TY  - JOUR
LB  - 158.
AU  - Axelsen, MB
AU  - Eshed, I
AU  - Horslev-Petersen, K
AU  - Steengaard-Petersen, K
AU  - Hetland, ML
AU  - Moller, JM
TI  - A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without added adalimumab reduces synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: the opera magnetic resonance imaging sub-study
J2  - Arthritis Rheum
PY  - 2013
VL  - 65
SP  - S1199
ER  - 
TY  - JOUR
LB  - 159.
AU  - Axelsen, MB
AU  - Eshed, I
AU  - Horslev-Petersen, K
AU  - Stengaard-Pedersen, K
AU  - Hetland, ML
AU  - Moller, J
TI  - A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial
J2  - Ann Rheum Dis
PY  - 2015
VL  - 74
SP  - 867
EP  - 875
UR  - https://doi.org/10.1136/annrheumdis-2013-204537
ER  - 
TY  - JOUR
LB  - 160.
AU  - Hørslev-Petersen, K
AU  - Hetland, ML
AU  - Junker, P
AU  - Pødenphant, J
AU  - Ellingsen, T
AU  - Ahlquist, P
TI  - Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial
J2  - Ann Rheum Dis
PY  - 2014
VL  - 73
SP  - 654
EP  - 661
UR  - https://doi.org/10.1136/annrheumdis-2012-202735
ER  - 
TY  - JOUR
LB  - 161.
AU  - Hørslev-Petersen, K
AU  - Hetland, ML
AU  - Junker, P
AU  - Podenphant, J
AU  - Ellingsen, T
AU  - Ahlqvist, P
TI  - Very high remission rates are achieved by methotrexate and intraarticular glucocorticoids independent of induction therapy with adalimumab; year 2 clinical results of an investigator-initiated randomised, controlled clinical trial of early, rheumatoid arthritis (opera)
J2  - Arthritis Rheum
PY  - 2013
VL  - 65
SP  - S1148
ER  - 
TY  - JOUR
LB  - 162.
AU  - Hetland, ML
AU  - Junker, P
AU  - Poodenphant, J
AU  - Ellingsen, T
AU  - Ahlquist, P
AU  - Lindegaard, H
TI  - Remission rates increase substantially by adding adalimumab to methotrexate and intra-articular glucocorticoid in patients with early rheumatoid arthritis-1-year results of investigator-initiated, double-blinded randomized clinical trial (OPERA)
J2  - Ann Rheum Dis
PY  - 2013
VL  - 71
ER  - 
TY  - JOUR
LB  - 163.
AU  - Emery, P
AU  - Smolen, JS
AU  - Fleischmann, R
AU  - Van Vollenhoven, R
AU  - Florentinus, S
AU  - Santra, S
TI  - Achieving long-term comprehensive disease control with adalimumab and methotrexate in patients with early rheumatoid arthritis in the optima study
J2  - Ann Rheum Dis
PY  - 2013
VL  - 71
UR  - https://doi.org/10.1136/annrheumdis-2012-eular.2628
ER  - 
TY  - JOUR
LB  - 164.
AU  - Kavanaugh, A
AU  - Emery, P
AU  - Fleischmann, R
AU  - Van Vollenhoven, R
AU  - Pavelka, K
AU  - Durez, P
TI  - Withdrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: results of a phase 4, double-blind, placebo-controlled trial
J2  - Rheumatol
PY  - 2012
VL  - 51
SP  - iii29
EP  - iii30
ER  - 
TY  - JOUR
LB  - 165.
AU  - Kavanaugh, A
AU  - Emery, P
AU  - Fleischmann, R
AU  - Van Vollenhoven, RF
AU  - Pavelka, K
AU  - Durez, P
TI  - Withdrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: results of a phase 4, double-blind, placebo-controlled trial
J2  - Arthritis Rheum
PY  - 2011
VL  - 63
IS  - (Suppl. 1)
ER  - 
TY  - JOUR
LB  - 166.
AU  - Kavanaugh, A
AU  - Van Vollenhoven, RF
AU  - Emery, P
AU  - Shaw, JW
AU  - Cifaldi, MA
AU  - Florentinus, S
TI  - Patient-reported outcomes in early rheumatoid arthritis patients failing to achieve stable low disease activity: comparing addition of adalimumab to methotrexate monotherapy with maintenance on adalimumab plus methotrexate
J2  - Arthritis Rheum
PY  - 2012
VL  - 64
SP  - S162
EP  - S1S3
ER  - 
TY  - JOUR
LB  - 167.
AU  - Smolen, J
AU  - Fleischmann, RM
AU  - Emery, P
AU  - Van Vollenhoven, RF
AU  - Guerette, B
AU  - Santra, S
TI  - Treating rheumatoid arthritis to target: outcomes and predictors in early rheumatoid arthritis patients treated with adalimumab plus methotrexate, methotrexate alone, or methotrexate plus subsequent adalimumab
J2  - Arthritis Rheum
PY  - 2011
VL  - 63
ER  - 
TY  - JOUR
LB  - 168.
AU  - Wolff, M
AU  - Zhou, ZY
AU  - Signorovitch, J
AU  - Shaw, JW
AU  - Ganguli, A
TI  - Cost-effectiveness of different treatment sequences including adalimumab in the treat-to-target framework for early rheumatoid arthritis in Germany
J2  - Arthritis Rheum
PY  - 2013
VL  - 65
SP  - S753
ER  - 
TY  - JOUR
LB  - 169.
AU  - Edmonds, J
AU  - Lassere, M
AU  - Carlton, K
TI  - OSRA – a therapeutic target-driven RCT: update on safety during combination DMARD & biological therapies
J2  - Ann Rheum Dis
PY  - 2005
VL  - 64
SP  - 451
EP  - 452
ER  - 
TY  - JOUR
LB  - 170.
AU  - Edmonds, J
AU  - Lassere, M
AU  - Sharp, JT
AU  - Bird, P
TI  - Objectives study in RA (OSRA): a RCT defining the best clinical target for disease activity control in RA
J2  - Ann Rheum Dis
PY  - 2007
VL  - 66
SP  - 325
ER  - 
TY  - JOUR
LB  - 171.
AU  - Pablos, J
AU  - Navarro, F
AU  - Blanco, F
AU  - Roman-Ivorra, J
AU  - Alonso, A
AU  - Martin-Mola, E
TI  - Maintenance of response in patients with rheumatoid arthritis (RA) after switching to TCZ administered alone compared to the combination of TCZ and MTX
J2  - Ann Rheum Dis
PY  - 2015
VL  - 74
SP  - 476
EP  - 477
UR  - https://doi.org/10.1136/annrheumdis-2015-eular.4501
ER  - 
TY  - JOUR
LB  - 172.
AU  - Pavelka, K
AU  - Akkoc, N
AU  - Al-Maini, M
AU  - Zerbini, CA
AU  - Bao, C
AU  - Karateev, DE
TI  - Impact of combination etanercept-DMARD induction therapy in active rheumatoid arthritis: interim results of an international treat-to-target study conducted in regions with limited biologic access
J2  - Ann Rheum Dis
PY  - 2015
VL  - 74
SP  - 1035
UR  - https://doi.org/10.1136/annrheumdis-2015-eular.1689
ER  - 
TY  - JOUR
LB  - 173.
AU  - Pavelka, K
AU  - Akkoc, N
AU  - Al-Maini, M
AU  - Zerbini, C
AU  - Bao, CD
AU  - Karateev, D
TI  - Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study with a double-blind, placebo-controlled maintenance phase
J2  - J Clin Rheumatol
PY  - 2016
VL  - 22
SP  - 127
EP  - 128
ER  - 
TY  - JOUR
LB  - 174.
AU  - Aletaha, D
AU  - Funovits, J
AU  - Breedveld, FC
AU  - Sharp, J
AU  - Segurado, O
AU  - Smolen, JS
TI  - Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment
J2  - Arthritis Rheum
PY  - 2009
VL  - 60
SP  - 1242
EP  - 1249
UR  - https://doi.org/10.1002/art.24433
ER  - 
TY  - JOUR
LB  - 175.
AU  - Breedveld, FC
AU  - Keystone, E
AU  - Heijde, D
AU  - Landewe, R
AU  - Smolen, J
AU  - Guerette, B
TI  - Initial combination therapy with adalimumab plus methotrexate leads to better long-term outcomes than with either monotherapy in patients with early rheumatoid arthritis: 8-year results of an open-label extension of a phase 3 trial
J2  - Arthritis Rheum
PY  - 2011
VL  - 63
ER  - 
TY  - JOUR
LB  - 176.
AU  - Breedveld, FC
AU  - Weisman, MH
AU  - Kavanaugh, AF
AU  - Cohen, SB
AU  - Pavelka, K
AU  - van Vollenhoven, R
TI  - The PREMIER study – a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
J2  - Arthritis Rheum
PY  - 2006
VL  - 54
SP  - 26
EP  - 37
UR  - https://doi.org/10.1002/art.21519
ER  - 
TY  - JOUR
LB  - 177.
AU  - Emery, P
AU  - Genovese, MC
AU  - van Vollenhoven, R
AU  - Sharp, JT
AU  - Patra, K
AU  - Sasso, EH
TI  - Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis
J2  - J Rheumatol
PY  - 2009
VL  - 36
SP  - 1429
EP  - 1441
UR  - https://doi.org/10.3899/jrheum.081018
ER  - 
TY  - JOUR
LB  - 178.
AU  - Keystone, E
AU  - Weinblatt
AU  - Haraoui, B
AU  - Guerette, B
AU  - Mozaffarian, N
AU  - Patra, K
TI  - Clinical and radiographic implications of time to treatment response in patients with early rheumatoid arthritis
J2  - Reumatol Clin Supl
PY  - 2011
VL  - 7
SP  - 145
ER  - 
TY  - JOUR
LB  - 179.
AU  - Keystone, EC
AU  - Breedveld, FC
AU  - van der Heijde, D
AU  - Landewé, R
AU  - Florentinus, S
AU  - Arulmani, U
TI  - Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension
J2  - J Rheumatol
PY  - 2014
VL  - 41
SP  - 5
EP  - 14
UR  - https://doi.org/10.3899/jrheum.130543
ER  - 
TY  - JOUR
LB  - 180.
AU  - Keystone, EC
AU  - Breedveld, FC
AU  - Kavanaugh, A
AU  - Van Riel, P
AU  - Patra, K
AU  - Pangan, A
TI  - Sustained clinical remission and response for early RA patients with adalimumab and methotrexate initial combination therapy: 5-year results of the PREMIER trial
J2  - J Rheumatol
PY  - 2009
VL  - 36
IS  - Suppl. 11
SP  - 2598
ER  - 
TY  - JOUR
LB  - 181.
AU  - Keystone, EC
AU  - Breedveld, FC
AU  - Van Der Heijde, D
AU  - Landewe, R
AU  - Florentinus, S
AU  - Arulmani, U
TI  - Long-term impact of delaying combination therapy with adalimumab plus methotrexate by 2 years in patients with early rheumatoid arthritis: final 10-year results of the premier trial
J2  - Ann Rheum Dis
PY  - 2013
VL  - 72
UR  - https://doi.org/10.1136/annrheumdis-2013-eular.718
ER  - 
TY  - JOUR
LB  - 182.
AU  - Keystone, EC
AU  - Breedveld, FC
AU  - Van Der Heijde, D
AU  - Landewe, R
AU  - Florentinus, S
AU  - Arulmani, U
TI  - Long-term impact of delaying combination therapy with adalimumab plus methotrexate by 2 years in patients with early rheumatoid arthritis: final 10-year results of the premier trial
J2  - Arthritis Rheum
PY  - 2013
VL  - 65
SP  - S595
UR  - http://onlinelibrary.wiley.com/doi/10.1002/art.38216/full
ER  - 
TY  - JOUR
LB  - 183.
AU  - Keystone, EC
AU  - Van Der Heijde, D
AU  - Landewe, R
AU  - Patra, K
AU  - Perez, JL
AU  - Pangan, AL
TI  - Better long-term inhibition of radiographic progression in early RA with adalimumab and methotrexate initial combination therapy: 5-year results of the PREMIER trial
J2  - J Rheumatol
PY  - 2009
VL  - 36
SP  - 2573
EP  - 2574
ER  - 
TY  - JOUR
LB  - 184.
AU  - Strand, V
AU  - Rentz, AM
AU  - Cifaldi, MA
AU  - Chen, N
AU  - Roy, S
AU  - Revicki, D
TI  - Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study
J2  - J Rheumatol
PY  - 2012
VL  - 39
SP  - 63
EP  - 72
UR  - https://doi.org/10.3899/jrheum.101161
ER  - 
TY  - JOUR
LB  - 185.
AU  - van der Heijde, D
AU  - Breedveld, FC
AU  - Kavanaugh, A
AU  - Keystone, EC
AU  - Landewe, R
AU  - Patra, K
TI  - Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER
J2  - J Rheumatol
PY  - 2010
VL  - 37
SP  - 2237
EP  - 2246
UR  - https://doi.org/10.3899/jrheum.100208
ER  - 
TY  - JOUR
LB  - 186.
AU  - Keystone, EC
AU  - Weinblatt, ME
AU  - Haraoui, B
AU  - Guerette, B
AU  - Mozaffarian, N
AU  - Patra, K
TI  - Clinical and radiographic implications of time to treatment response in patients with early rheumatoid arthritis
J2  - Arthritis Rheum
PY  - 2010
VL  - 62
SP  - 1102
ER  - 
TY  - JOUR
LB  - 187.
AU  - Bananis, E
AU  - Smolen, J
AU  - Van Vollenhoven, R
AU  - Pederson, R
AU  - Szumski, A
AU  - Koenig, A
TI  - Relationship between clinical response and radiographic outcomes in patients with moderate rheumatoid arthritis in the preserve trial
J2  - Int Med
PY  - 2013
VL  - 43
SP  - 15
EP  - 16
ER  - 
TY  - JOUR
LB  - 188.
AU  - Kobelt, G
TI  - Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved
J2  - Value Health
PY  - 2014
VL  - 17
SP  - 537
EP  - 544
UR  - https://doi.org/10.1016/j.jval.2014.04.005
ER  - 
TY  - JOUR
LB  - 189.
AU  - Pavelka, K
AU  - Burgos-Vargas, R
AU  - Miranda, P
AU  - Guzman, R
AU  - Yen, JH
AU  - Izzi, MA
TI  - Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia
J2  - Int J Clin Rheumatol
PY  - 2014
VL  - 9
SP  - 415
EP  - 430
UR  - https://doi.org/10.2217/ijr.14.27
ER  - 
TY  - JOUR
LB  - 190.
AU  - Pavelka, K
AU  - Khalil, A
AU  - Koenig, AS
AU  - Szumsk, A
AU  - Youseif, EA
AU  - Bananis, E
TI  - Maintenance of response with conventional- or reduced-dose etanercept therapy or biologic free after induction of response with etanercept -methotrexate therapy in patients with moderately active rheumatoid arthritis participating in the PRESERVE study in Europe, Latin America, and Asia
J2  - Int J Rheum Dis
PY  - 2012
VL  - 15
SP  - 54
EP  - 55
ER  - 
TY  - JOUR
LB  - 191.
AU  - Pavelka, K
AU  - Szekanecz, Z
AU  - Damjanov, N
AU  - Majdan, M
AU  - Nasonov, E
AU  - Mazurov, V
TI  - Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study
J2  - Clin Rheumatol
PY  - 2013
VL  - 32
SP  - 1275
EP  - 1281
UR  - https://doi.org/10.1007/s10067-013-2240-4
ER  - 
TY  - JOUR
LB  - 192.
AU  - Smolen, J
AU  - Szumski, A
AU  - Marshall, L
AU  - Koenig, AS
TI  - Baseline predictors of remission with combination etanercept -methotrexate therapy in moderately active rheumatoid arthritis: interim results of the preserve trial
J2  - Arthritis Rheum
PY  - 2011
VL  - 63
ER  - 
TY  - JOUR
LB  - 193.
AU  - Smolen, JS
AU  - Collier, D
AU  - Szumski, A
AU  - Jones, H
AU  - Marshall, L
TI  - Characteristics of responding versus non-responding moderate rheumatoid arthritis patients treated with etanercept plus methotrexate
J2  - Arthritis Rheum
PY  - 2014
VL  - 66
SP  - S1091
EP  - S10S2
ER  - 
TY  - JOUR
LB  - 194.
AU  - Smolen, JS
AU  - Collier, D
AU  - Szumski, A
AU  - Jones, H
AU  - Marshall, L
TI  - Effect of disease duration on clinical outcomes in moderate rheumatoid arthritis patients treated with etanercept plus methotrexate in the preserve study
J2  - Arthritis Rheumatol
PY  - 2014
VL  - 66
SP  - S812
EP  - S8S3
ER  - 
TY  - JOUR
LB  - 195.
AU  - Smolen, JS
AU  - Ilivanova, E
AU  - Hall, S
AU  - Irazoque-Palazuelos, F
AU  - Park, MC
AU  - Kotak, S
TI  - Low disease activity or remission induction with etanercept 50 mg and methotrexate in moderately active rheumatoid arthritis: Maintenance of response and safety of etanercept 50 mg, 25 mg, or placebo in combination with methotrexate in a randomized double-blind study
J2  - Arthritis Rheum
PY  - 2011
VL  - 63
IS  - Suppl. 12
SP  - 4041
ER  - 
TY  - JOUR
LB  - 196.
AU  - Smolen, JS
AU  - Nash, P
AU  - Durez, P
AU  - Hall, S
AU  - Ilivanova, E
AU  - Irazoque-Palazuelos, F
TI  - Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
J2  - Lancet
PY  - 2013
VL  - 381
SP  - 918
EP  - 929
UR  - https://doi.org/10.1016/S0140-6736(12)61811-X
ER  - 
TY  - JOUR
LB  - 197.
AU  - Smolen, JS
AU  - Szumski, A
AU  - Koenig, AS
AU  - Jones, TV
TI  - Predictors of loss of clinical remission with etanercept 50 mg, 25 mg or placebo combined with methotrexate in moderate rheumatoid arthritis patients: results of the preserve trial
J2  - Ann Rheum Dis
PY  - 2013
VL  - 71
UR  - https://doi.org/10.1136/annrheumdis-2012-eular.2621
ER  - 
TY  - JOUR
LB  - 198.
AU  - Strand, V
AU  - Jones, TV
AU  - Li, W
AU  - Koenig, AS
AU  - Kotak, S
TI  - Factors that impact work productivity in the preserve trial: a randomized controlled trial of combination etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis
J2  - Arthritis Rheum
PY  - 2012
VL  - 64
SP  - S777
ER  - 
TY  - JOUR
LB  - 199.
AU  - Strand, V
AU  - Jones, TV
AU  - Li, W
AU  - Koenig, AS
AU  - Kotak, S
TI  - Predictors of work impairment in a randomized controlled trial of etanercept-methotrexate therapy in patients with moderate rheumatoid arthritis
J2  - Ann Rheum Dis
PY  - 2013
VL  - 71
UR  - https://doi.org/10.1136/annrheumdis-2012-eular.1385
ER  - 
TY  - JOUR
LB  - 200.
AU  - Szekanecz, Z
AU  - Yen, JH
AU  - Miranda, P
AU  - Szumski, A
AU  - Bananis, E
AU  - Kotak, S
TI  - Impact of etanercept-methotrexate therapy on patient-reported outcomes in moderately active rheumatoid arthritis (RA) patients of Europe, Latin America, and Asia
J2  - Value Health
PY  - 2012
VL  - 15
SP  - A674
UR  - https://doi.org/10.1016/j.jval.2012.08.419
ER  - 
TY  - JOUR
LB  - 201.
AU  - Proudman, SM
AU  - Conachan, PG
AU  - Richardson, C
AU  - Griffiths, B
AU  - Green, MJ
AU  - McGonagle, D
TI  - Treatment of poor-prognosis early rheumatoid arthritis – a randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone
J2  - Arthritis Rheum
PY  - 2000
VL  - 43
SP  - 1809
EP  - 1819
UR  - https://doi.org/10.1002/1529-0131(200008)43:8<1809::AID-ANR17>3.0.CO;2-D
ER  - 
TY  - JOUR
LB  - 202.
AU  - Scott, DL
AU  - Kowalczyk, A
TI  - Clinical trials: tight control in early RA pays off in the long run
J2  - Nat Rev Rheumatol
PY  - 2010
VL  - 6
SP  - 623
EP  - 624
UR  - https://doi.org/10.1038/nrrheum.2010.174
ER  - 
TY  - JOUR
LB  - 203.
AU  - Scott, IC
AU  - Ibrahim, F
AU  - Scott, DL
AU  - Lewis, CM
TI  - The impact of intensive treatment and remission on health-related quality of life in rheumatoid arthritis
J2  - Lancet
PY  - 2016
VL  - 387
SP  - 90
UR  - https://doi.org/10.1016/S0140-6736(16)00477-3
ER  - 
TY  - JOUR
LB  - 204.
AU  - Solomon, DH
AU  - Lee, SB
AU  - Zak, A
AU  - Corrigan, C
AU  - Agosti, J
AU  - Bitton, A
TI  - Implementation of treat-to-target in rheumatoid arthritis through a learning collaborative: rationale and design of the TRACTION trial
J2  - Semin Arthritis Rheum
PY  - 2016
VL  - 46
SP  - 81
EP  - 87
UR  - https://doi.org/10.1016/j.semarthrit.2016.02.009
ER  - 
TY  - JOUR
LB  - 205.
AU  - Danre, A
AU  - Fautrel, B
AU  - Alfaiate, T
AU  - Pham, T
AU  - Morel, J
AU  - Labous, ED
TI  - What discriminates best flares in rheumatoid arthritis (RA)? A subanalysis of the strass treatment tapering in RA study
J2  - Arthritis Rheum
PY  - 2014
VL  - 66
SP  - S610
EP  - S6S1
ER  - 
TY  - JOUR
LB  - 206.
AU  - Danre, A
AU  - Gossec, L
AU  - Pham, T
AU  - Morel, J
AU  - Alfaiate, T
AU  - Dernis, E
TI  - Effects of TNF alpha-blockers tapering on occurrence of patient-perceived flares in rheumatoid arthritis: a subanalysis of strass
J2  - Ann Rheum Dis
PY  - 2014
VL  - 73
ER  - 
TY  - JOUR
LB  - 207.
AU  - Fautrel, B
AU  - Pham, T
AU  - Alfaiate, T
AU  - Gandjbakhch, F
AU  - Foltz, V
AU  - Morel, J
TI  - Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study)
J2  - Ann Rheum Dis
PY  - 2016
VL  - 75
SP  - 59
EP  - 67
UR  - https://doi.org/10.1136/annrheumdis-2014-206696
ER  - 
TY  - JOUR
LB  - 208.
AU  - Fautrel, B
AU  - Gandjbakhch, F
AU  - Foltz, V
AU  - Pham, T
AU  - Morel, J
AU  - Alfaiate, T
TI  - Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: Clinical and structural impact of a step-down strategy trial based on progressive spacing of TNF-blocker injections (STRASS trial)
J2  - Ann Rheum Dis
PY  - 2013
VL  - 72
UR  - https://doi.org/10.1136/annrheumdis-2013-eular.271
ER  - 
TY  - JOUR
LB  - 209.
AU  - Fautrel, B
AU  - Pham, T
AU  - Morel, J
AU  - Alfaiate, T
AU  - Dernis, E
AU  - Gaudin, P
TI  - Results of the STRASS trial regarding impact of progressive spacing of TNF-blocker injections in rheumatoid arthritis patients in DAS28 remission: Is there a difference between drugs – adalimumab and etanercept – or their mode of use-monotherapy or combination?
J2  - Arthritis Rheum
PY  - 2013
VL  - 65
SP  - S1150
ER  - 
TY  - JOUR
LB  - 210.
AU  - Fautrel, B
AU  - Pham, T
AU  - Morel, J
AU  - Alfaiate, T
AU  - Dernis, E
AU  - Gaudin, P
TI  - Impact of progressive spacing of TNF-blocker injections on signs and symptoms of rheumatoid arthritis patients in DAS28 remission: the STRASS randomized controlled trial
J2  - Ann Rheum Dis
PY  - 2013
VL  - 72
UR  - https://doi.org/10.1136/annrheumdis-2013-eular.708
ER  - 
TY  - JOUR
LB  - 211.
AU  - Fautrel, B
AU  - Pham, T
AU  - Tubach, F
AU  - Alfaiate, T
AU  - Morel, J
AU  - Dernis, E
TI  - Tapering TNF-blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28-driven step-down strategy randomized controlled trial
J2  - Arthritis Rheum
PY  - 2012
VL  - 64
IS  - Suppl. 12
SP  - 4169
EP  - 4170
ER  - 
TY  - JOUR
LB  - 212.
AU  - Pham, T
AU  - Morel, J
AU  - Alfaiate, T
AU  - Dernis, E
AU  - Gaudin, P
AU  - Brocq, O
TI  - Predictive factors of relapse or persistent stable remission for rheumatoid arthritis (RA) patients in remission in a TNF blocker-spacing strategy trial (STRASS trial)
J2  - Arthritis Rheum
PY  - 2013
VL  - 65
SP  - S1021
ER  - 
TY  - JOUR
LB  - 213.
AU  - Vanier, A
AU  - Tubach, F
AU  - Alfaiate, T
AU  - Mariette, X
AU  - Fautrel, B
TI  - Step-down strategy of spacing TNF-blockers injections for established rheumatoid arthritis in remission: a within randomized control trial based cost-utility analysis
J2  - Arthritis Rheum
PY  - 2015
VL  - 67
ER  - 
TY  - JOUR
LB  - 214.
AU  - Dale, J
AU  - Purves, D
AU  - McConnachie, A
AU  - McInnes, I
AU  - Porter, D
TI  - Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy
J2  - Arthritis Care Res
PY  - 2014
VL  - 66
SP  - 19
EP  - 26
UR  - https://doi.org/10.1002/acr.22218
ER  - 
TY  - JOUR
LB  - 215.
AU  - Dale, J
AU  - Purves, D
AU  - McConnachie, A
AU  - Porter, D
AU  - McInnes, IB
TI  - Tightening up: musculoskeletal ultrasound could further individualise treatment decisions in early rheumatoid arthritis patients treated by a step-up DMARD escalation regimen
J2  - Arthritis Rheum
PY  - 2012
VL  - 64
SP  - S1129
ER  - 
TY  - JOUR
LB  - 216.
AU  - Dale, J
AU  - Stirling, A
AU  - McInnes, IB
AU  - Porter, D
TI  - Targeting ultrasound remission in early rheumatoid arthritis – results of the TaSER study
J2  - Arthritis Rheum
PY  - 2013
VL  - 65
SP  - S338
EP  - S3S9
ER  - 
TY  - JOUR
LB  - 217.
AU  - Todoerti, M
AU  - Scirè, CA
AU  - Boffini, N
AU  - Bugatti, S
AU  - Montecucco, C
AU  - Caporali, R
TI  - Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis
J2  - Ann N Y Acad Sci
PY  - 2010
VL  - 1193
SP  - 139
EP  - 145
UR  - https://doi.org/10.1111/j.1749-6632.2009.05367.x
ER  - 
TY  - JOUR
LB  - 218.
AU  - Claessen, SJ
AU  - Hazes, JM
AU  - Huisman, MA
AU  - van Zeben, D
AU  - Luime, JJ
AU  - Weel, AE
TI  - Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial
J2  - BMC Musculoskelet Dis
PY  - 2009
VL  - 10
SP  - 71
UR  - https://doi.org/10.1186/1471-2474-10-71
ER  - 
TY  - JOUR
LB  - 219.
AU  - de Jong, PH
AU  - Hazes, JM
AU  - Barendregt, PJ
AU  - Huisman, M
AU  - van Zeben, D
AU  - van der Lubbe, PA
TI  - Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial
J2  - Ann Rheum Dis
PY  - 2013
VL  - 72
SP  - 72
EP  - 78
UR  - https://doi.org/10.1136/annrheumdis-2011-201162
ER  - 
TY  - JOUR
LB  - 220.
AU  - de Jong, PH
AU  - Hazes, JM
AU  - Han, HK
AU  - Huisman, M
AU  - van Zeben, D
AU  - van der Lubbe, PA
TI  - Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial
J2  - Ann Rheum Dis
PY  - 2014
VL  - 73
SP  - 1331
EP  - 1339
UR  - https://doi.org/10.1136/annrheumdis-2013-204788
ER  - 
TY  - JOUR
LB  - 221.
AU  - de Jong, PH
AU  - Quax, RA
AU  - Huisman, M
AU  - Gerards, AH
AU  - Feelders, RA
AU  - de Sonnaville, PB
TI  - Response to glucocorticoids at 2 weeks predicts the effectiveness of DMARD induction therapy at 3 months: post hoc analyses from the tREACH study
J2  - Ann Rheum Dis
PY  - 2013
VL  - 72
SP  - 1659
EP  - 1663
UR  - https://doi.org/10.1136/annrheumdis-2012-202152
ER  - 
TY  - JOUR
LB  - 222.
AU  - De Jong, PHP
AU  - Hazes, J
AU  - Barendregt, PJ
AU  - Huisman, AM
AU  - Van Zeben, D
AU  - Van Der Lubbe, PA
TI  - Combination of disease-modifying antirheumatic drugs prohibits the need of early initiation of biologicals, independent of glucocorticosteroids. A clinical trial to investigate different induction therapies in early rheumatoid arthritis
J2  - Arthritis Rheum
PY  - 2011
VL  - 63
IS  - (Suppl. 1)
ER  - 
TY  - JOUR
LB  - 223.
AU  - De Jong, PHP
AU  - Hazes, JMW
AU  - Han, KH
AU  - Huisman, AM
AU  - Van Zeben, D
AU  - Van Der Lubbe, PA
TI  - Initial triple DMARD therapy is more efficient than methotrexate monotherapy in recent onset rheumatoid arthritis; 1-year data of a randomized clinical trial (tREACH)
J2  - Arthritis Rheum
PY  - 2013
VL  - 65
SP  - S717
ER  - 
TY  - JOUR
LB  - 224.
AU  - De Jong, PHP
AU  - Weel, AEAM
AU  - Luime, JJ
AU  - Barendregt, PJ
AU  - Gerards, AH
AU  - Van Der Lubbe, PA
TI  - Better cost-effectiveness and worker productivity in triple DMARD therapy versus methotrexate monotherapy in early rheumatoid arthritis; cost-utility analysis of the tREACH trial
J2  - Arthritis Rheum
PY  - 2013
VL  - 65
SP  - S753
EP  - S7S4
ER  - 
TY  - JOUR
LB  - 225.
AU  - Van der Elst, K
AU  - De Cock, D
AU  - Vecoven, E
AU  - Arat, S
AU  - Meyfroidt, S
AU  - Joly, J
TI  - Are illness perception and coping style associated with the delay between symptom onset and the first general practitioner consultation in early rheumatoid arthritis management? An exploratory study within the CareRA trial
J2  - Scand J Rheumatol
PY  - 2016
VL  - 45
SP  - 171
EP  - 178
UR  - https://doi.org/10.3109/03009742.2015.1074278
ER  - 
TY  - JOUR
LB  - 226.
AU  - van Tuyl, LHD
AU  - Lems, WF
AU  - Voskuyl, AE
AU  - Kerstens, P
AU  - Garnero, P
AU  - Dijkmans, BAC
TI  - Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial
J2  - Ann Rheum Dis
PY  - 2008
VL  - 67
SP  - 1574
EP  - 1577
UR  - https://doi.org/10.1136/ard.2008.090712
ER  - 
TY  - JOUR
LB  - 227.
AU  - Verschueren, P
AU  - Esselens, G
AU  - Westhovens, R
TI  - Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis
J2  - Rheumatology
PY  - 2008
VL  - 47
SP  - 59
EP  - 64
UR  - https://doi.org/10.1093/rheumatology/kem288
ER  - 
TY  - JOUR
LB  - 228.
AU  - Verschueren, P
AU  - De Cock, D
AU  - Corluy, L
AU  - Joos, R
AU  - Langenaken, C
AU  - Taelman, V
TI  - Remission induction with DMARD combinations and glucocorticoids is not superior to remission induction with MTX monotherapy and glucocorticoids: week 52 results of the high-risk group from the carera trial
J2  - Ann Rheum Dis
PY  - 2015
VL  - 74
SP  - 139
UR  - https://doi.org/10.1136/annrheumdis-2015-eular.4018
ER  - 
TY  - JOUR
LB  - 229.
AU  - Yoo, DH
AU  - Racewicz, A
AU  - Brzezicki, J
AU  - Yatsyshyn, R
AU  - Arteaga, ET
AU  - Baranauskaite, A
TI  - A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study
J2  - Arthritis Res Ther
PY  - 2016
VL  - 18
UR  - https://doi.org/10.1186/s13075-016-0981-6
ER  - 
TY  - JOUR
LB  - 230.
AU  - Bansback, N
AU  - Marra, C
AU  - Tsuchiya, A
AU  - Anis, A
AU  - Guh, D
AU  - Hammond, T
TI  - Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis
J2  - Arthritis Rheum
PY  - 2007
VL  - 57
SP  - 963
EP  - 971
UR  - https://doi.org/10.1002/art.22885
ER  - 
TY  - JOUR
LB  - 231.
AU  - Oostenbrink, JB
AU  - Koopmanschap, MA
AU  - Rutten, FF
TI  - Standardisation of costs: the Dutch Manual for Costing in economic evaluations
J2  - PharmacoEconomics
PY  - 2002
VL  - 20
SP  - 443
EP  - 454
UR  - https://doi.org/10.2165/00019053-200220070-00002
ER  - 
TY  - BOOK
LB  - 232.
AU  - Oostenbrink, JB
AU  - Koopmanschap, MA
AU  - Rutten, FF
TI  - Manual for Cost Analyses, Methods and Standard Prices for Economic Evaluations in Health Care
CY  - Amstelveen
PB  - Dutch Health Insurance Executive Board
PY  - 2004
ER  - 
TY  - JOUR
LB  - 233.
AU  - Koopmanschap, MA
AU  - Rutten, FF
AU  - van Ineveld, BM
AU  - van Roijen, L
TI  - The friction cost method for measuring indirect costs of disease
J2  - J Health Econ
PY  - 1995
VL  - 14
SP  - 171
EP  - 189
UR  - https://doi.org/10.1016/0167-6296(94)00044-5
ER  - 
TY  - JOUR
LB  - 234.
AU  - van den Hout, WB
AU  - Tijhuis, GJ
AU  - Hazes, JM
AU  - Breedveld, FC
AU  - Vliet Vlieland, TP
TI  - Cost effectiveness and cost utility analysis of multidisciplinary care in patients with rheumatoid arthritis: a randomised comparison of clinical nurse specialist care, inpatient team care, and day patient team care
J2  - Ann Rheum Dis
PY  - 2003
VL  - 62
SP  - 308
EP  - 315
UR  - https://doi.org/10.1136/ard.62.4.308
ER  - 
TY  - JOUR
LB  - 235.
AU  - van den Berg, B
AU  - Brouwer, W
AU  - van Exel, J
AU  - Koopmanschap, M
TI  - Economic valuation of informal care: the contingent valuation method applied to informal caregiving
J2  - Health Econ
PY  - 2005
VL  - 14
SP  - 169
EP  - 183
UR  - https://doi.org/10.1002/hec.893
ER  - 
TY  - JOUR
LB  - 236.
AU  - van Roijen, L
AU  - Essink-Bot, ML
AU  - Koopmanschap, MA
AU  - Bonsel, G
AU  - Rutten, FF
TI  - Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire
J2  - Int J Technol Assess Health Care
PY  - 1996
VL  - 12
SP  - 405
EP  - 415
UR  - https://doi.org/10.1017/S0266462300009764
ER  -